

Ежемесячный научный медицинский журнал

# Интер–медикал

№ 5 (11) / 2015

## **Редакционная коллегия:**

Т.В. Аверин, докт. мед.наук, профессор (Волгоград)  
С.К. Баклаков, канд. мед.наук (Москва)  
Б.Д. Балавин, докт. мед.наук, профессор (Москва)  
Ф.А. Вервин, докт. биол. наук, профессор (Москва)  
Е.З. Веревкин, докт. тех. наук, профессор (Ростов)  
С.Т. Герычев, докт. мед. наук,(Санкт\_Петербург)  
Н.Ю. Дороменко, докт. мед.наук, член-корр. РАМН (Новосибирск)  
П.Р. Кравченко, докт. хим. наук, профессор (Ставрополь)  
К.О. Левин, докт. мед.наук, академик РАН (Астана, Казахстан)  
И.Т. Мирчук, докт. тех. наук, (Москва)  
Н.У. Полежаев, докт. мед.наук, (Саратов)  
В.Ш., Корчевикус профессор (Прага, Чехия)  
Я.Д. Ковернан, докт. биол. наук, академик РАН (Москва)  
А.Г. Зукен, канд. биол. наук (Мюнхен, Германия)  
В.П. Сергиев, докт. мед.наук, (Мюнхен, Германия)  
М. Скурник, профессор (Хельсинки, Финляндия)

Статьи, поступающие в редакцию, рецензируются. За достоверность сведений, изложенных в статьях, ответственность несут авторы. Мнение редакции может не совпадать с мнением авторов материалов. При перепечатке ссылка на журнал обязательна. Материалы публикуются в авторской редакции.

## **Адрес редакции:**

Алтуфьевское шоссе, дом 27 А, строение 9, 127106, а/я 341.  
E-mail: [info@inter-medical.ru](mailto:info@inter-medical.ru) ; <http://www.inter-medical.ru/>

## **Учредитель и издатель**

Международное Научное Объединение "Inter-Medical"  
Отпечатано в типографии Алтуфьевское шоссе, дом 27 А, строение 9, 127106, а/я 341  
Тираж 1000 экз.



**Ответственный редактор:**

Т.В.Аверин, докт. мед.наук, профессор (Волгоград)

**Международный редакционный совет:**

С.К. Баклаков, канд. мед.наук (Москва)

Б.Д. Балавин, докт. мед.наук, профессор (Москва)

Ф.А. Вервин, докт. биол. наук, профессор (Москва)

Е.З. Веревкин, докт. тех. наук, профессор (Ростов)

С.Т. Герычев, докт. мед. наук, (Санкт\_Петербург)

Н.Ю. Дороменко, докт. мед.наук, член-корр. РАМН (Новосибирск)

П.Р. Кравченко, докт. хим. наук, профессор (Ставрополь)

К.О. Левин, докт. мед.наук, академик РАН (Астана, Казахстан)

И.Т. Мирчук, докт. тех. наук, (Москва)

Н.У. Полежаев, докт. мед.наук, (Саратов)

В.Ш. Корчевикус профессор (Прага, Чехия)

Я.Д. Ковернан, докт. биол. наук, академик РАН (Москва)

А.Г. Зукен, канд. биол. наук (Мюнхен, Германия)

В.П. Сергиев, докт. мед.наук, (Мюнхен, Германия)

М. Скурник, профессор (Хельсинки, Финляндия)

Журнал зарегистрирован Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций.

**Художник:** © Дмитрий Варенов

**Верстка:** © Андрей Каплинский

© Inter-Medical 2014

# СОДЕРЖАНИЕ

<p>Медицинские науки .....5</p> <p>.....10</p> <p>.....14</p> <p>.....17</p> <p>.....22</p> <p>.....23</p> <p>.....26</p> <p>.....28</p> <p>.....32</p> <p>.....35</p> <p>.....37</p>	<p>.....40</p> <p>.....42</p> <p>.....46</p> <p>.....49</p> <p>.....51</p> <p>.....54</p> <p>.....56</p> <p>.....59</p> <p><i>и другие естественные науки</i></p> <p>.....63</p>
---	--

· ” · ·	-
RHAP NTICUM CARTHAMOIDES.....	67
· ·	-
« - » .....	72
· ·	-
(SIPHONAPTERA)	-
(RODENTIA)	-
.....	75
· ” - · ” · ·	-
.....	80
· ” · ” · ·	-
( ) .....	83
· ” · ·	-
-	-
FRAUDATRIX	-
EUPENTACTA	-
.....	91

### Хи и еские ауки

· ” · ·	-
· ” · ·	-
.....	96
· ” · ” · ·	-
.....	98

### Фар ацевти еские ауки

· ” · ” · ·	-
-	-
.....	103

### Ветери ар ые ауки

· ” · ” · ·	-
-	-
« - »	-
.....	106

# Медицинские науки

Манрикян М.Е.<sup>1</sup>, Маркарян М.М.<sup>2</sup>

1. . . . ,

2.

(1997 .) : 7372 (6, 12, 15, 35-44, 65 ), 10  
 (4143 ) - -  
 (917). , -  
 , - 100% -  
 47.8%, - 94%

**SUMMARY**

*Manrikyan M.E., Markaryan M.M.*

*Dental morbidity of population in the Republic of Armenia*

*The aim of the research-are determining the causes of the growth of dental disease in Armenia and improvement of treatment methods and prevention measures to improve dental health.*

*Materials and methods-we analyzed 7372 WHO`s medical cards for assessment dental status (1997) in following age groups (6,12,15,35-44,65 and more) covering a population of 10 region and a capital.*

*We done medical checkup of population (4145people) and dentists (917). European indicators of dental health are defined for schoolchildren of Yerevan. The results indicate that the prevalence of dental caries of temporary and permanent teeth tends to increase, in adults remains at the same level-100%. The prevalence of periodontal lesions in children are 47.8% on the average and 94% or more for adults. In Armenia there are a reliable tendency to increase dental morbidity and continuation of process should be expected unless the factots which are affecting on the development of diseases wil not be changed in favorable direction. To improve dental health on the population level not only specialists but also health authorities efforts are needed, by the introduction of appropriate prevention programs.*

*Keywords: ey age groups, prevention, stomatological morbidity*

2006 .


6- 12-

[2,5].

2 - 4

[4].





.1. (%) 12

100% , - 12- -

27.7; - 50% . 70%,

23 , -26 , - 15%, 52%, 32% .

40% ( 1). - 4-5

0.1% . 15- -


( .2). 59% . 0.7% 73%

6- 24% , - -

- 11% . 13%, - 4-5 , -

- 16.4% 49% .

4-5 0.1% .



.2.

	, %				
6					
	29.3	0.43	0.06	0.01	0.5±0.9
.	16.8	0.25	0.028	0.002	0.28±0.7
	-	<0.001	<0.001	<0.05	<0.001
12					
	93.4	3.1	0.31	0.07	3.48±2.29
.	81.7	1.8	0.48	0.02	2.3±1.8
	-	<0.001	<0.001	<0.001	<0.01
15					
	93.0	3.8	0.5	0.1	4.4±2.7
.	93.6	2.79	1.27	0.06	4.12±2.5
	-	<0.001	<0.001	<0.001	<0.001
35-44					
	99.5	5.05	0.91	5.06	11.02±5.79
.	100	3.04	3.45	6.53	11.85±5.48
	-	<0.001	<0.001	p>0.1	p<0.05
65					
	100	2.5	0.1	23.4	26.0±8.1
.	100	1.7	0.1	25.9	27.7±5.6
	-	<0.01	p>0.1	<0.001	p<0.001

o -

.

,

,

(35-44 ) , 31%

15- 2-

,

17%

( 2).

12 - 34-39%.

12- 44% 15- : 38%

«

»,

13-15%

100%

9 % 12 15 16-18  
 - 87% 12- , 94%  
 15- 18  
 12 ,

2

(%)

				4-5	6	
6						
	76.1	8.9	13.0	-	-	2.0
.	88.9	3.5	7.5	0.1	-	-
12						
	30.4	16.4	51.5	1.1	-	0.6
.	50.4	18	31.5	0.1	-	-
15						
	27.1	14.6	57.3	0.9	-	0.1
.	40.7	18.3	40.6	0.4	-	-
35-44						
	6.0	9.0	39.9	14.4	2.4	28.3
.	2.8	7.9	45.9	12.9	0.3	30.2
65						
	1.3	0.5	11.6	11.9	5.2	69.5
.	0.27	0.82	11.26	28.02	5.77	53.8

:  $p < 0,05$ .

12- -  
 84%,  
 13%.  
 47% , 20%  
 91 % 12- 95% 15- 18 . , 27% ; 70%  
 43% , 41%  
 19%  
 63%  
 59.9% - , 63.8% -  
 - 70%  
 71% 52%.

1. . . . . , 1997. - 76 .
2. . . . . , 2009 -236 .
3. . . . . , 2008. – 444 .
4. Towards Better Oral Health in Children. Health Education Board for Scotland (HEBS). <http://www.scotland.gov.uk/education/schoolmeals> ( 3.04.2007).
5. WHO: The World Oral Health Report 2003. – Geneva: WHO, 2003. – 38p.

### **Варданян И.Ф.**

2003

574 6,12,15

2003 . 10%

2013 . 6- 0,29% , 16,28%, 12 – 0,74% - 1,57% – 0 24,05% .

#### *Summary.*

*Vardanyan I.F., Yerevan State Medical University after M.Heratsi*

*Problems of organization of dental care for child population of Syunik region of Armenia.*

*Solving the problem of reducing the incidence of dental diseases of the population is one of the important problems. The aim of the research- assessment the level of dental care for child population of Syunik region of Armenia and a comparative analysis of monitoring data of 2003 to identify the problems in this area.*

*Materials and methods-we calculated the level of dental care among 574 schoolchildren in following age groups (6, 12, 15) rural and urban areas Syunik region of Armenia, carried out a comparative analysis of the data. Results of the study. The level of dental care in 2003 was low in all of groups of children independently of location – it was lower than 10%. In 2013 the situation changed - level increase to unsatisfactory: on the average, in 6 age level increase to 16,28%, in 12 age children – to 1,57% and in teenagers increased to 24,05%. Children often receive dental care from a dentist in adult clinic because the region has no specialized children's dental clinic, which also affects the quality of dental care.*

*Key words: child population, stomatological morbidity*

[3,4].

2003

[5].

[1,6,8,9,10].

[7].

( )

[2,7].

2003

6,12,15

574

- 303 2003 . 271- 2013 .

( )


=100% - [( + )/ ]x100%

;

( , , )


:  
 <10% —  
 10—49% —  
 50—74% —  
 75% > —

( ) ( )  
 ) 2013  
 2003 . , 6  
 2003 .  
 0,32%,  
 2013 . 0,58%,  
 0 16,25%.  
 12 15  
 0,74% 12,27% 0 13,76%  
 « » ,  
 ( .1).



1.

, 11,82% 10,64%  
 ; 24% 12-  
 2003 . 25% 15- 6-  
 18,2% 11,3%  
 , 23,3% - 15  
 10% 12-  
 - 1,57%,  
 2013 . ( .2).



2. 2003 2013 .

« , 2007, .3-10. » , -

?» « 3. . . . -

?» - - -

. - // ... . . . ,

75% , 2013 ., 306 . 4. - -

, - - -

, . - // ... . . . , -

, 2005 ., 296 5. - -

. - - -

, - - -

6. . . . -2009. - 20 . - -

, - - -

. - , 2000. - 34 . 7. . . . -

. . . . // . . . , 2008, 200 . 8. . . . -

- // - -

. -2001. - .3. - .9-15 - - -

2. . . . . . . . . . // - -

« - - -

9. Broadbent J.M, Thomson W.M, Poulton R. Trajectory patterns of dental caries experience in the permanent dentition to the fourth decade of life. J Dent Res. 2008 Jan;87(1):69-72.

10.Leake J.L, Birch S. Public policy and the market for dental services. //Community Dent Oral Epidemiol. 2008 Aug;36(4):287-95.

---

*Воротникова Н.А.<sup>1</sup>, Эйберман А. .<sup>2</sup>, Шульгина Е.Н.<sup>3</sup>, Балашова Е.В.<sup>4</sup>*

1

2

3

4

*Summary. In article one of important problems of pediatrics is considered - optimization of therapy of the*



; , (0,25/ 60; TEVA, ). OMRON C-29, 56 16 12 : 27 - , 17 - 14 , 8 - 12 - 17 - 13 - 16 - 10 - 19 ; (asthma control test), 12-16 - 19 [6]. » ( 5-12 ) , « 19 ; 12-16 - 19 56 , - 27 : 20 1 16 ( - 9,25 ± 1,08), 7 1 14 ( 6,14 ± 0,2); - 2 , - 14 , - 11 . - 17 , - 10 1 15 ( - 5,8 ± 2,01), 7 4 14 ( - 6,4 ± 1.81). - 2- 11 ( - 12 : 7 - 5,14 ± 2,03), 5 2- 7 ( 4,6 ± 1,12). 3 , -IgE-

-7 .. : -5 .. - 3 . 56 « » / 15,3 ± 2,7 19 ± 3,9 . 7,3 ± 0,3 -9,5 ± 0,02 ; -11,36 ± 0,12 ; -8,4 ± 0,11 - 12,1 ± 2,35 IgE . 125 1. ( ) 250 (1 ) 1 . 250 (1 ) 2 . (500 / ), - 1000 ( 2 2 ) 1500 ( 3 2 ) 2. . 3. - 3 , - 4 . 4 - 6 , - 7-8 . 1. . // Consilium medicum. . - 2008. - 1.- .7 – 10. 2. . . . . 3. // . - 2010. 2. - .60 – 68. 3. : . . ; . - 2006. - 280 .



4. // . - 6. - 2011. - .5 - 11. 6. "
5. .., 2008. - 82 . - 2012. - 182 . 7. . . - 2010. - . 89, 4. - . 61. //

**Ганцгорн Е.В.<sup>1</sup>, Алексеев А.Н.<sup>2</sup>**

<sup>1</sup> - . . . .

<sup>2</sup> - . 1

« » , 1

2 ( 2) - -

2 -

**ABSTRACT**

*Type 2 diabetes mellitus (T2DM) is one of the most important problems of modern clinical endocrinology and medicine in general, due to the high, ever-increasing prevalence of the disease and the frequent development of vascular and neurological complications of the disease.*

*The article describes a clinical case of a combination of T2DM with acute stroke (CVA) in terms of hospital treatment of the patient.*

*Key words: type 2 diabetes, stroke.*

. 2, , - ( ) [1]. 2 11-43%,

2030 . 2, 438 (4-6%). 2 - [4].  
 . ( 6–8% ), 90% 2 [5].

2, 1,5-4 , : . / . : 11.02.13 . 2 63  
 - 2-6 , 65 ; ; ;

; ; ; ; ; : -  
; ; , ; -  
• , -  
• 160/100 ;  
• 3 ; =16. :  
• 11.02.2013 10 ; -  
160/100 -  
• 4,5 ; - 5  
• :  
• ; 1-3  
• :  
• ( 2)  
• : ; , , -  
6 -  
STATUS PRESENS COMMUNIS  
• ; , , c -  
• ; , -  
• ; , 9/8/7 -  
162 , 83 , =31.6, - 115 -  
• : ( -

4. .  
 5. .  
 6. ( .  
 7. ).  
 8. -  
 120 -  
 170/90 . .  
 8-10 .  
 2 .  
 11.02.2013 .  
 11.02.2013 .  
 12.02.2013 .  
 ;  
 ;  
 ;  
 ;

Показатель	Норма	Полученные результаты
Эритроциты	3,7-4,7*10 <sup>12</sup> /л	4,0*10 <sup>12</sup> /л
Гемоглобин	115-145г/л	130г/л
Тромбоциты	180-320*10 <sup>12</sup> /л	297*10 <sup>12</sup> /л
Цветной показатель	0,85-1,05	1
Базофилы	0-1%	1%
Лейкоциты	3,8-9,8*10 <sup>9</sup> /л	6,5*10 <sup>9</sup> /л
Эозинофилы	0,5-5%	2%
Н. палочкоядерные	1-6%	1%
Н. сегментоядерные	47-72%	67%
Лимфоциты	18-37%	26%
Моноциты	3-11%	4%
<b>СОЭ</b>	<b>2-15мм/ч</b>	<b>59мм/ч</b>

11.02.2013 .

Показатель	Норма	Полученные результаты
Общий белок	62-85 г/л	74.2 г/л
Амилаза	20-220 U/l	42 U/l
ALT	5-49 U/l	28.6 U/l
AST	5-49 U/l	30.9 U/l
<b>Глюкоза</b>	<b>4.1-5.9 mmol/l</b>	<b>8.79 mmol/l</b>
Общий билирубин	5.0-21.0 mkmol/l	17.2 mkmol/l
Мочевина	2.1-8.2 mkmol/l	4.5 mkmol/l
Креатинин	62-124 mkmol/l	62.9 mkmol/l
<b>Холестерин</b>	<b>3.6-6.2 mmol/l</b>	<b>8.55 mmol/l</b>
ХС ЛВП	0.78-2.20 mmol/l	0.84 mmol/l
<b>ХС ЛОНП</b>	<b>1.68-4.53 mmol/l</b>	<b>5.23 mmol/l</b>
<b>Триглицериды</b>	<b>0.70-1.70 mmol/l</b>	<b>2.63 mmol/l</b>
<b>Коэффициент атерогенности</b>	<b>0.98-4.51 mmol/l</b>	<b>9.18 mmol/l</b>

11.02.2013 .

Общ. св-ва	Колич. – цвет. – уд. вес –
	прозрач. – реакция –
Химич. исслед.	Белок - 0,022 г/л Желч. Пигменты
	<b>Сахар – 23,2 ммоль/л</b>
	Уробилин -
	Ацетон -
Микроскопические Исследования	Эпителий переходный -
	« почечный – не обнаружены плоский - 0-1 х'
	Лейкоциты - 1-2 х'
	Эритроциты - 0-1х'
	« зернистые - не обнаружены
	« восковидные - не обнаружены
	Цилиндроды - не обнаружены
	Слизь – + (обнаружена)
	Соли - кристаллы мочевой кислоты
	Бактерии - не обнаружены

11.02.2013 .  
 - 3,4 / ; Na – 138 /

11.02.2013 . 13.02.2013 .  
 : -  
 : 1 .  
 - 14.02.2013 .  
 « » . :  
 - : (HbA1c),  
 - , -  
 11.02.2013 . :  
 : (HbA1c):  
 HbA1c= 10,53%  
 1,3 .. - : 780,1  
 - :  
 , 30-40%. - :  
 - (11.02.2013 ).  
 S<D 40%. - :  
 , III , 3 ,  
 4 ( ) .

Показатель	Норма	Полученные результаты
Холестерин	3.6-6.2 mmol/l	<b>8,35</b> mmol/l
ЛВП	0.78-2.20 mmol/l	<b>0,84</b> mmol/l
ЛОНП	1.68-4.53 mmol/l	<b>7,71</b> mmol/l
Триглицериды	0.70-1.70 mmol/l	<b>2,50</b> mmol/l
Коэффициент атерогенности	0.98-4.51 mmol/l	<b>2,18</b> mmol/l

Даты	13.02.2013 г.	18.02.2013 г.	25.02.2013 г.
Натошак	7,85 ммоль/л	9,51 ммоль/л	7,90 ммоль/л
Через 2 часа	9,78 ммоль/л	10,60 ммоль/л	11,42 ммоль/л
Через 4 часа	9,93 ммоль/л	9,83 ммоль/л	5,71 ммоль/л

: 2, [5].  
 1 I . -  
 • «  
 ( )=20 / \* \*83 =1660 / . 2,  
 • , -  
 : , -  
 - , -  
 12 10.00 12 \ : 22.00 [2]. «  
 ( 30 .) , , -  
 : 1-  
 -8,5 ; 2- -5 ; -8 ; - [3].  
 ( : 1. . . . .  
 HbA1c< 7%); // . - 2009. - 1.  
 ( ; < 130/80 . . ); 2. . , . . . .  
 ( ) ; -  
 (100 / ), . / . . . . , 7-  
 2 - )/ . - 2015. - 112 .  
 / - 3. . . . .  
 2- : , -  
 // . - 2013. - 4 (52) - . 57-  
 11:1, 2 - 62.  
 -5:1 [4].  
 <15 , -  
 ( « »).  
 2 , -  
 6-40% [1].  
 2,

*Доровская А.И.<sup>1</sup>, Коршевер Н.Г.<sup>2</sup>, Барегамян Л.А.<sup>3</sup>*

1

2

3

5

65

**CAREER MANAGEMENT IN MEDICAL ORGANIZATIONS: DOCUMENTS DEVELOPMENT**

*Resume. The research objective is to analyze the state of medical staff career documentation in medical organizations. Materials and methods. Using a specially developed chart, we extracted the data on documents development in medical staff career management in 65 medical organizations of the city of Saratov and Saratov region. Results. We found out, that for many cases documents for medical staff career management have not been developed. Conclusion. It is worthwhile to develop the suggested list of documents for increasing the efficiency of medical staff career management.*

*Key words. Documents, career management, medical organizations.*

( )

[1-5 .].

.1

.1,

65

60% ( ):

45% ; ; - ;  
 - ;  
 - , -  
 19% , - 4- . 1

	%
	1,5
	15,4
	18,5
	6,2
	3,1
	44,6
	10,8
	70,8
	18,5
	76,9
	44,6
	86,2
	66,2
	12,3

1. : . . / . . -  
 : „ 2008.- 176 .  
 2. :  
 //  
 . - 2011. - 2. - . 77-83.  
 3. : , 2012. - 352 .  
 4. : . . /  
 - . . . .  
 1998. 384 .  
 5. : . . . .  
 , 2001. 408 .

**Климкович Н.Н.<sup>1</sup>, Красько О.В.<sup>2</sup>**

<sup>1</sup> « . . . . » , . . . .  
<sup>2</sup> « . . . . » , . . . .

IPSS-R  
 18 60  
 IPSS-R,  
 CD95. CD95  
 , IPSS-R, CD95.

*Summary. IPSS-R demonstrates the high predictive value in MDS, even in isolated age cohort of 18 to 60 years. In addition to the criteria included in the predictive system IPSS-R, a statistically significant prognostic value in the multivariate model is the expression of CD95. Expression of CD95 is the only factor that is associated with all events in MDS, it increases the risk of low value transition in the state of transformation, and in the terminal state.*

*Keywords: myelodysplastic syndromes, prognosis, IPSS-R, CD95.*

( )  
 (HR)  
 p<0,05.  
 R 3.0.1 [4].  
 IPSS-R; IPSS-R  
 ( , , )  
 CD95  
 CD95 (Fas/APO 1)  
 (IPSS-R - Revised International prognostic scoring system) [3].  
 CD95  
 [2].  
 « - ».  
 [1]. : «1» - , «2» - , «3» - .  
 «1»  
 12  
 26,6 %  
 60 11,3%.  
 ( )  
 «2») 12  
 45,1%.  
 70  
 18 60 c (49,3% 60 ).  
 ( «3») 28,3%  
 2008 . 12 39,4% 60 .



2. ScienceRise. 2015; 1/3(6):29-37.
3. Greenberg P.L., Tuechler H., Schanz J., Sanz G., Garcia-Manero G., Sole F., Bennett J.M., Bowen D., Fenaux P., Dreyfus F., Kantarjian H., Kuendgen A., Levis A., Malcovati L., Cazzola M., Cermak J., Fonatsch Ch., Le Beau M.M., Slovak M.L., Krieger O., Luebbert M., Maciejewski J., Magalhaes S.M. M., Miyazaki Y., Pfeilstocker M., Sekeres M., Sperr W.R., Stauder R., Tauro S., Valent P., Vallespi T., van de Loosdrecht A.A., Germing U., Haase D. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012; 120:2454-65.
4. R: A language and environment for statistical computing. R Foundation for Statistical Computing/R Core Team [Electronic resource]. Vienna, Austria, 2013. – Available at: <http://www.R-project.org/>.

**Ляпунов А.Ю.**

26 Ia1 – Ib1

«<sup>99m</sup>Tc»

( )

« »

*Optimization of the extent of surgery in organ-preserving treatment for invasive cervical cancer*

*Introduction: The study included 26 patients with stage Ia1 – Ib1 cervical cancer who underwent organ-preserving surgery (transabdominal trachelectomy). To visualize sentinel lymph nodes, lymphoscintigraphy with injection of radioactive lymphotropic isotope, <sup>99m</sup>Tc-labelled nanocolloid, was performed the day before surgery. Intraoperative identification of sentinel lymph nodes using gamma probe was carried out to assess which lymph nodes had taken up the radionuclide. Detection of sentinel lymph nodes in cervical cancer patients can accurately predict the pelvic lymph node status, assess the stage of the disease, individualize the extent of surgery and determine indications for organ-preserving surgery.*

*Keywords: cervical cancer, sentinel lymph nodes, trachelectomy.*

7 (9,8%)

FIGO IA2-IB2

( )

,16].

		-	[17,9,11,18,21].	-
	[1, ,19,].	-		-
	,	-	«	»
		-		-
		-	,	
	26	-	,	
	I	-	-	
	,	-	,	
		-	,	
	I	-	,	
	: I 1	-	,	
7	(27%); I 2 – 8 (31%); Ib1- 11	-		
(42%).		-		
		-	[10,12, 13,17].	
	99mTc.	-		
	:	-	1.	
( )		-	.	.
-	Gamma Finder II ( ),	-	2.	.
		-	.	.
	[].	-	99M	-
	,	-	.	2002.
	21 (80,8%)	-	1.	. 114-121.
,	( )	-	3.	.
45	26	-	.	.
,		-	?	
	2	-	.	2010.
		-	5.	. 71-77.
		-	4.	.
	(37,7%),	-	.	.
		-	5.	.
28,8%	17,4%	-	.	2008.
	9,6%	-	3.	. 86-93.
6,5%.		-	.	.
	,	-	6.	.
		-	.	2006.
		-	1.	. 70.
		-	.	.
	[3,6,8,14,15].	-	.	1998.
»	«	-	6.	. 32-36.
		-	7.	.
		-	.	.
		-	,	:
		-	«	».
		-	.	2011.
		-	22.	4.
		-	.	. 97-105.
		-	8.	.
		-	.	.
		-	.	.

9. . 2010. 1. . 23-25

10. NF-κ . 2012. . 46. 3. . 452.

11. . 2011. 4. . 64-68.

12. 3. . 22-25.

13. 2005. . 25. 3. . 37-40.

14. , 2009

72-78. . 2011. 2. .

15. . . . . -

16. . 2012. 3. . 28-33.

17. " . , 2009

18. Dobrodeev A.Yu., Zav'yalov A.A., Musabaeva L.I., Tuzikov S.A., Miller S.V., Smyshlyaeva E.A. Results of the patients of the combined treatment of non-small cell lung cancer with intraoperative radioterapy and cysplatinum. . 2012. 3. . 16-24.

19. Musabaeva L.I., Lisin V.A., Zheravin A.A., Anisenya I.I., Bepalov V.I., Kol'chuzhkin A.M., Cheryashkina G.A. Radiation therapy in patients with locomotooor system tumors after organ-preserving surgery with implants from titanium alloys. . 2004. . 49. 6. . 64-70.

20. Spirina L.V., Yunusova N.V., Kondakova I.V., Kolomiets L.A., Koval V.D., Chernyshova A.L. ASSOCIATION OF GROWTH FACTORS, HIF-1 AND NF- B EXPRESSION WITH PROTEASOMES IN ENDOMETRIAL CANCER. Molecular Biology Reports. 2012. . 39. 9. . 8655-8662.

**Манрикан Г.Е.**

15  
6.4±2.1.

4 7

38%

#### Summary

*Manrikyan G.E., Characteristics changes of dentoalveolar system among children with breath disturbances. Yerevan State Medical University after M.Heratsi*

*The result of orthodontics treatment mainly depends on the LOR pathology treatment and the measure of nasal breathing normalization. The aim of the research- At the expense of working on the diagnostics algorithms and planning of the patients' complex - preventive rehabilitation will be improved the effectiveness of patients' treatment from dentofacial malocclusion which is accompanied by the breathing functions offensives. Material and Methods. There was made an investment of orthodontics status and the breath parafunction inside of 15 patients' age of from 4 to 7 years old which includes: clinical and biometrical investments. Results of the study. It was clarified the most renowned dentofacial system anomalies inside of children's investing groups considered the distal occlusion of tooth rows, as the presence of a pharyngeal tonsil increscent the child throws back a head. By the way the child can rid of epiglottis under the pressure of lung while leaving back lower jaw. After removal complicated causes of nasal breathing otolaryngologist in a patients' group where have not completed early orthodontics treatment of dent - facial system anomaly the distal dentition ratio observed in 83% cases.*

*The main observation in the group of children also specified a high intensity of dental caries where the indicator of DMF in average was consisted of 6.4±2.1. he oral sanitation of mouth, control for symmetry and consistency of teeth considered important development in preventive measures anomaly of dentoalveolar system. During a patients' treatment from dent - facial system anomaly and complicated nasal breathing should be recommended the complex treatment plan. Early invested ethological factors and control of tooth curves makes serendipity to confirm development progress in dent facial system anomaly on a bone level.*

*Keywords: dentoalveolar disorders, malfunction of breath*

[9,10,12].

[4,7,11].

[14].

, V-  
 [1,5,13].  
 [6,8].  
 [2]  
 3-  
 ( );  
 ( )  
 [2]  
 ;  
 ;  
 ( )  
 ;  
 ( , )  
 15  
 4 7  
 38%  
 26%.

6.4±2.1 ( ); +  
 =0.4±0.1. : =4.8±1.6, =1.0±0.3,  
 4-7

[3].

28,9%  
 8%.

I 13%

1. , . . . . . -  
 // -  
 . 2002. - 2. - . 28-29. -  
 2. . . . . -  
 // -  
 2002. - . 37-39. -  
 3. . . . . -  
 ( - - -  
 ). - - -  
 : . . . . . -  
 , 2003 - 47 . -  
 4. . . . . -  
 : -  
 . - 2007. - 55 . -  
 5. . . . . -  
 // . 2001.- 5. - . 54-  
 56. - - -  
 6. . . . . -  
 // -  
 .

- 181  
2013. - . 176 -
7. P.O.,  
2010. - 6. - . 47-53.
8. // -  
2007.-45 .
9. // -  
.- 2005.- 3,- .43-45.
10. B.C.,  
.- 2005,- 3.- .32-39.
11. -  
.-2010.- 3. - . 65-68
12. Becker D.G., Bloom J. Five techniques that i cannot live without in revision rhinoplasty// Facial. Plast. Surg. 2008.- Vol.24.-N 3.Aug.- P.358-364.
13. Beugre, J. B., Kouassi A. L., Sonan N. K. [et al.] Quantification of initial malocclusion according to the mode of breathing in black African children. // Odontostomatol. Trop. 2004. - Vol. 27, 106. - P. 15-21.
14. Posnick J.C., Fantuzzo J. J. Troost T. Simultaneous Intra-nasal Procedures to Improve Chronic Obstructive Nasal Breathing in Patients Undergoing Maxillary (Le FortI) osteotomy // Journal of Oral and Maxillofacial Surgery. - 2007. - Vol. 65, n 11,- P.2273-2281.

### Мишура Л.Г.<sup>1</sup>, Родионов Г.Г.<sup>2</sup>

1 « », -  
2 . . . , . -

IV 0,0003 / . I

*Effect of cytochrome C concentrations on mitochondrial respiratory chain of lymphocytes.*

#### SUMMARY

*The aim of this work was to study the effect of the drug cytochrome C in different concentrations on mitochondrial electron transfer chain (ETC) and related effects. The experiment was performed with the use of donor lymphocytes that were incubated with a solution of cytochrome C in varying concentrations. It is found that the best effect on the energy metabolism of cells has Cytochrome C concentrations close to 0.0003 mmol / ml. This increases the activity of I and IV of the respiratory chain complexes and improved coupling of components between a ETC. Also, the results make it possible to judge the increase in the proportion of aerobic oxidation-reduction processes in the energy metabolism of the cells under the influence of cytochrome C*

*Keywords: respiratory chain, cytochrome C, lymphocytes*

NaCl) ( =7,4) -  
 ( CAT X-120, ).  
 -  
 -  
 ,  
 -  
 Q10  
 -  
 (0,154 M NaCl, pH=7,4, +37 °),  
 - «  
 » [4]. Q10, -  
 ,  
 -  
 «  
 »  
 ,  
 /  
 5 ( ~0,0003 / ).  
 [4]. ,  
 -  
 (0,0106; 0,0021;  
 0,0011; 0,0003 / ).  
 -  
 2°  
 ,  
 (I-IV),  
 ( , , )  
 ).  
 -  
 ( -CoQ-  
 I) (EC 1.6.5.3),  
 ( I-III) (EC 1.6.2.1);  
 [1]. : CoQ-  
 -  
 C II-III) (EC 1.3.2.2);  
 ( IV) (EC 1.9.3.1)  
 ( IV) [1].  
 -  
 [7,8]  
 [5]. ( ). KONE Specific Basic [3]  
 .  
 in Plus (Roche Diagnostics, Cobas Integra 400 ).  
 vitro. :  
 - I, I-III, II-III  
 ( - ) (IV  
 ),  
 ( IV  
 50-65 , ). ( ) [4].  
 Lymphoprep ,  
 TM Tube (0,154 ,

- IV -  
 - , 34%.  
 -  
 U- t-  
 p < 0,05. 7 (0,0021 / ) - I -  
 PASW Statistics 18. 44%  
 ( 26%), I-III  
 « » (0,0003 16%, II-III  
 / ) I 17%, IV  
 12%, ( 59%. I/IV 3,5 , I-  
 33%), III/IV 2 , II-III/IV -  
 I-III II-III 2,8 . -  
 IV IV -  
 28%. I/IV 2 , 12%.  
 13%, I-III/IV II-III/IV 33%, -  
 24% 19%. 22%.  
 IV  
 23%, 35 (0,0106 / ) - I  
 15% 24%. - 11%  
 4 (0,0011 / ) - I - 18%), I-III  
 12% 18%, II-III  
 ( 14%, IV -  
 56%), , I-III/IV 21%, II-III/IV  
 6%, II-III 9%.  
 37%, IV -  
 31%. I/IV 61%, I-  
 III/IV 53%, II-III/IV -  
 9%. -  
 1

, n=10 ( ±SD) Td [A025A>12.C0268026F427



... / ... ..  
 ... ..  
 ... .. , 2008. - 102 ..  
 3. ... / ... ..  
 - 0,0003 ... .. , 2006. - 108.  
 / ( ... / - 4. ... / ... ..  
 ), ( I IV ... // ... -  
 12% 28%), ( ... ..  
 ) IV ( - 5. 2006. - 6 .9-12  
 36%. ... ..  
 - - 2007. - .49, 5. .385-394  
 - - 6. Protection against oxidative damage of  
 erythrocyte membrane by the flavonoid  
 quercetin and its relation to iron chelating  
 activity / Ferrali M. et al.// FEBS Letters 1997,  
 416., pp.123-129  
 ( 15% 24%). 7. Sukhjit K.S. Mitochondrial electron transport  
 chain complexes in aging rat brain and  
 lymphocytes. /Sukhjit K.S., Gurcharan K. //  
 Biogerontology. 2003, Vol.4., No.1, pp.19-29  
 1. : / ... - 8. Shinde S. Respiratory-chain enzyme activities  
 in isolated mitochondria of lymphocytes from  
 patients with Parkinson's disease: Preliminary  
 study. / Shinde S. et Pasupathy K. // Neurology  
 2006. Vol. 54, No. 4, pp. 390-393  
 2. :  
 3

**Пунченко О.Е.<sup>1</sup>, Потеряева Д. <sup>2</sup>**

1

2

3

*Proteus vulgaris.*

: *Proteus vulgaris*

( *P. vulgaris* ) 0,1 %.

**Abstract**

The objective was to study the morphological and phenotypic changes of Enterobacteriaceae that have developed resistance to antiseptics in vitro. For this aim used isolated from clinical samples of a culture of *Proteus vulgaris*. The minimum inhibiting concentration of antiseptics was determined in a liquid medium, and then induced the resistance. After induction of resistance also determined the sensitivity of the strains to the antibiotic and bacteriophages. The results: *P. vulgaris* was characterized by typical morphological properties and was positive in the Dienes phenomenon. *P. vulgaris* was resistant to ciprofloxacin, intermediate resistance to ampicillin and ceftibuten. Re-examining the same properties of *P. vulgaris* showed that there were hemolytic phenomenon, resistance to ampicillin, sensitivity to ciprofloxacin. Modified strains was positive in the Dienes phenomenon.

**Key words:** antiseptic, phenotypic change, bacterial resistance, Enterobacteriaceae.

*Proteus vulgaris*.

*Pseudomonas aeruginosa*

[5].

[2],

[1].

[3]

[4].

*P. vulgaris*

0,1 %.

*P. vulgaris*

« »

*P. vulgaris*

1. *Pseudomonas aeruginosa* *Staphylococcus aureus* //

2. - 2014. - 3. - .72-77.

3. , 2014. - 32 .

4. 4.2.1890-04.

5. . 2013 .

.- 2011. - 3. - .48-53.

**Разаева Н.А.**

[1, 17],  
 (FIGO)  
 [2, 13, 22].  
 [3, 6, 19].  
 IA2-IB2  
 « »  
 ( )  
 [2, 13, 22].  
 I  
 ( )  
 - 28,7 ± 4,5  
 26  
 3,8  
 3,2 3,9  
 0,9 1,4  
 1.  
 2.  
 99M  
 2002. 1. 114-121.  
 3.  
 ?  
 2010. 5. 71-77.  
 4.



5. . 2008. 3. . 86-93.
6. . 2006. 1. . 70.
7. 6. . 32-36. . 1998.
8. 22. 4. . 97-105. « . » . 2011. .
9. . 2010. 1. . 23-25
10. NF- $\kappa$  . 2012. . 46. 3. . 452.
11. . 2011. 4. . 64-68.
12. 3. . 22-25. . 2005.
13. . .
14. . , 2009
15. 72-78. . 2011. 2. .
16. . 2012. 3. . 28-33.
17. . , 2009
18. Dobrodeev A.Yu., Zav'yalov A.A., Musabaeva L.I., Tuzikov S.A., Miller S.V., Smyshlyaeva E.A. Results of the patients of the combined treatment of non-small cell lung cancer with intraoperative radioterapy and cysplatinum. . 2004. . 49. 6. . 64-70.
19. Musabaeva L.I., Lisin V.A., Zheravin A.A., Anisenya I.I., Bupalov V.I., Kol'chuzhkin A.M., Cheryashkina G.A. Radiation therapy in patients with locomotooor system tumors after organ-preserving surgery with implants from titanium alloys. . 2003. . 48. 2. . 56-62.
20. Spirina L.V., Yunusova N.V., Kondakova I.V., Kolomiets L.A., Koval V.D., Chernyshova A.L. ASSOCIATION OF GROWTH FACTORS, HIF-1 AND NF- B EXPRESSION WITH PROTEASOMES IN ENDOMETRIAL CANCER. Molecular Biology Reports. 2012. . 39. 9. . 8655-8662.

Разаева Н.А.

168

(65%),

(81%),

(68%).

(72%),

SUMMARY

hormonal and energetic status was studied in 168 patients with endometrial hyperplasia and endometrial cancer. The comparative analysis of hormonal status (LH, FSH, estrogen, progesterone, testosterone, prolactin, SHBG), energetic status (leptin, grelin, insulin) and the assessment of lipid and carbohydrate metabolisms were carried out for patients with proliferative processes in the endometrium with the evidence of metabolic syndrome and without it. The study showed that the changes in hormonal status were characterized by a high frequency of disturbances with development of hyperestrogenemia (72%), hypertestosteronemia (65%), hyperinsulinemia (81%) and hyperleptinemia (68%). Moreover, the LH level and LH/FSH index were increased and FSH and progesterone levels were decreased. Significant changes in both carbohydrate (hyperinsulinemia, insulin resistance) and lipid (hypercholesterolemia, hypertriglyceridemia) metabolisms were revealed. Mechanisms of hormonal correlations which underlie pathological endometrial process were suggested. Further investigations are required to individually prognosticate endometrial cancer process and to form the groups at high risk for endometrial cancer based on the assessment of hormonal and energetic balances, as well as to correct properly metabolic disorders in patients with endometrial hyperplasia and endometrial cancer.

Key words: endometrium, cancer, hyperinsulinemia, insulin resistance, leptin, hormonal balance, energetic balance.

	1	2
	52	52, 12±0,64
F IGO,	54,21±0,89	( =0,072). I
60%	30%	5-
[1,3,5,9,16].	36,8+0,45	I ( -
	27,5+21	-
	2 - 39,1+0,78;	2 - 25,9+0,54.
138	78	
	1	2
60		

	-		
	-		
	-		
	-		
	-		
( , - )	-	[4,7,17,18].	
( - )	-	1. . . . .	
	-	. . . . . ,2000. 199 .	
	-	2. . . . .	
	-	. . . . .	
	-		
	-	99M - .2002. 1. . 114-121.	
(1 2 ),	-	3. . . . .	
( 1 2) 72%,	-	. . . . .	
65%,	-		
58%,	-		
71%,	-		
SHBG	-	? .2010. 5. . 71-77.	
	-	4. . . . .	
	-		
	-	.2008. 3. . 86-93.	
	-	5. . . . .	
	-	. . . . .	
	-		
	-	.2006. 1. . 70.	
	-	6. . . . .	
	-	. . . . .	
	-	.1998. 6. . 32-36.	
	-	7. . . . .	
( , ,	-	. . . . .	
),	-		
	-	« . . . . . ».	
	-	.2011. . . . .	
	-	22. 4. . 97-105.	
	-	8. . . . .	
	-	. . . . .	
	-	. . . . .	
[8,10,12,15].	-		
( )	-		
	-	.2010. 1. . 23-25	
[2,6,13,19].	-	9. . . . .	
	-	. . . . .	
	-	. . . . .	

NF-κ

10. . 2012. . 46. 3. . 452. - . 2012. 3. . 28-33. -

11. . 2011. 4. . 64-68. - " . , 2009 -

12. 3. . 22-25. . 2005. - . 2012. 3. . 16-24. -

13. 2005. . 25. 3. . 37-40. - 18.Dobrodeev A.Yu., Zav'yalov A.A., Musabaeva L.I., Tuzikov S.A., Miller S.V., Smyshlyaeva E.A. Results of the patients of the combined treatment of non-small cell lung cancer with intraoperative radioterapy and cysplatinum. . 2004. . 49. 6. . 64-70. -

14. . , 2009 - 19.Musabaeva L.I., Lisin V.A., Zheravin A.A., Anisenya I.I., Bepalov V.I., Kol'chuzhkin A.M., Cheryashkina G.A. Radiation therapy in patients with locomotooor system tumors after organ-preserving surgery with implants from titanium alloys. . 2003. . 48. 2. . 56-62. -

15. 72-78. . 2011. 2. . 20. Spirina L.V., Yunusova N.V., Kondakova I.V., Kolomiets L.A., Koval V.D., Chernyshova A.L. ASSOCIATION OF GROWTH FACTORS, HIF-1 AND NF- B EXPRESSION WITH PROTEASOMES IN ENDOMETRIAL CANCER. Molecular Biology Reports. 2012. . 39. 9. . 8655-8662. -

**Хушвакова Н.Ж.<sup>1</sup>, Давронова Г.Б.<sup>2</sup>, Исакова Ю.Н.<sup>3</sup>**

( - . . . )

1

1, .7 703017.

2

703010

3

28. 140100

15

14,8%>

9,8%.

10,0% 3,3%

3,8

**SUMMARY**

The analysis of the effectiveness of ozone therapy with intravenous drug Cavinton the treatment of sensorineural hypoacusis of vascular genesis due to a chronic insufficiency of cerebral circulation in the vertebrobasilar pool in 15 patients. Marked positive effect - a positive trend according to additional tests: lower hearing thresholds at high frequencies (tone audiogram), improvement of cerebral hemodynamics (computer rheoencephalography), improved hearing afferentation mainly on stem auditory analyzer level (short-latency auditory evoked potentials). Improvement of cerebral hemodynamics in patients with ASNH for inclusion in the comprehensive treatment of intravenous infusion of ozone therapy resulted in a reduction in the tone of small arteries and facilitate venous drainage, provided that the normalization of blood supply in the basin of the internal carotid artery in 14.8%> observations in vertebrobasilar pool 9.8 %. These indicators were more significant compared with the same in the control group was 10.0% and 3.3% respectively. The risk of an adverse outcome in 3.8 times less than after the standard treatment.

Key words: Sensorineural hypoacusis, ozone therapy, traditional treatment, cavinton.

50%

10

[6].

[3].

[5].

[6,7].

[1].

( ) .

( ) :

( ) , , - -  
 , , - -  
 . , , - -  
 , , ( ), , ( ).  
 ( ) 40-50 ,  
 [5]. 2,0 .  
 , , - -  
 [3]. 400 , 1000 / -  
 5-7 . -  
 , , - -  
 , , - -  
 , , - -  
 , 5-8 -  
 400,0 -  
 , 2,0 -  
 , 0,6 / . 0,5-  
 , 2,5-4,8 / , -  
 40-50 . -  
 - : -  
 , , - 1/3 ,  
 , 14 (58,3%) -  
 ( 3-4 , -  
 , , - -  
 ). 2 (8,3%) , -  
 , ... - -  
 (29,1%), - (12,5%), -  
 : - (58,3%, 14 ) II (41,7%, 10 ) -  
 10 (41,7%) . -  
 I-II - -  
 : 24 128, 13 (54,1%) - -  
 , , - -  
 , , - -  
 25 65 .



1. . . . . , H.A. . . . . /  
 // . - 2002. - 2. - . 83.  
 6. . . . . / . . . . -  
 // . . . . . / 1-  
 , 2007. - . 50-97. . . . .  
 2. . . . . - 7. A.A. . . . . , 2002. - . 140-141.  
 : . . . . . / A.A. , . . . . // -  
 , 2002.- . 336. . . . .  
 3. . . . . — 2000. - . 88-92.  
 8. H.A. . . . .  
 , 2005. - . 200. . . . . ,  
 4. . . . . / H.A.  
 . . . . . //  
 2007. - . 11-16. - 2001. - 1. - . 20-21.  
 5. . . . .

**Хушвакова Н.Ж.<sup>1</sup>, Хамракулова Н.О.<sup>2</sup>, Исхакова Ф.Ш.<sup>3</sup>**

( : . . . . )  
 1 . . . . , . . . .  
 2 . . . . , . . . .  
 3 . . . . , . . . .

: (n=75),  
 0,002% (n=60),

135

91,4 %

**SUMMARY**

To determine the clinical efficacy of ozone therapy in patients with suppurative otitis media. Two groups: primary (n = 75), we obtain a five-day course of ozone therapy and washing the middle ear cavity preparation Dekasana 0.002% and a control (n = 60) who did not receive ozone therapy. This method allowed us to estimate the therapeutic effect in frequently ill patients in the pathology of the middle ear.







42%		, 25%	-	.	-	.	
, 25%							
-8%.							
			21±2,25.		13%		-
		50%	-	-			-
	48%	-	-			: 50%	-
65%.	25%				, 50%		-
		1,7	-		,		-
			7%,			4±1,3.	-
		2					-
					50%		-
				1,2			-
					16%,		-
							-
							-
							-
							-
			33%				-
	16%						-
							-
							-
							-
							-
							-
							-
							-
							-
							-
			67%				-
	33%						-
		7±2,75.					-
							-
							-
							-
							-
							-
							-
							-
							-
							-
							-
							-
							-
				1.			-
		50%					-

2. - 2010. - 4. - . 20-22. // - 266.  
 . . . . . 4. . . . .  
 . . . . . -  
 . . . . . -  
 // . 2008. 2. - . 31-33.  
 5. . . . . -  
 . . . . . -  
 3. . 2007. - 1 (42). - . 15-19. // -  
 . . . . . -  
 . . . . . -  
 // -  
 . 2011. 1. - .  
 17-20.  
 . - 2014. - 2. - . 263-

**Шаншавили Е.В.**

: 31  
 Bax Bcl-2, 53, - -  
 ( , -S- ) 2/4-  
 Bcl-2, -  
 , -  
 -

*Summary: xpression of tumor supressor protein p53, pro-and antiapoptotic proteins Bax and Bcl-2 as well as estrogen receptors (ER) and progesterone receptors (PR) and microvessel density in tumors were studied in 31 endometrial tumors by immunohistochemical methods. Activity of enzymes of estrogen synthesis and metabolism (aromatase, steroid sulfatase, total estrogen 2/4-hydroxylase activity, catechol-O-methyltransferase, glutathionetransferase) was assessed in the same tumors by radiometric, radioenzymatic and spectrophotometric methods. The study showed the correlation between the expression of antiapoptotic protein Bcl-2, neoangiogenesis intensity, ER and PR expressions and the activity of steroid sulfatase in malignant tumors of the endometrium. Futher investigations are required to individually prognosticate endometrial cancer process and to form the groups at high risk for endometrial cancer based on the the complex of immunohistochemical markers and the activity of some estrogen metabolic enzymes.*

*Key words: cancer, endometrium, estrogen metabolism, immunohistochemistry.*

« » [1,15,18]. [2,17,19]. -

Bcl-2 -  
 31 -  
 53, - Bax [4, 8,9]. cl-2-  
 Bcl-2, -  
 (CD31). -  
 ( 2/4- 12,7 % 29 % , -  
 -S- [10,12,13]. , 31 -  
 ). 58,1 -  
 ± 2,1 . Bax Bcl-2, -  
 Bcl-2 ( 2 - c ( 2/4-  
 n=19) Bcl-2 (Bcl-2 - (n=12). -S- ) -  
 , Bcl-2- Bcl-2- [5,7, 11]. -  
 Bax. Bcl-2- Bcl-2, -  
 , Bcl-2- 53. Bcl-2- -  
 73 % ). Bcl-2- ( -  
 Bcl-2, , Bcl-2 -  
 , Bcl-2- -  
 Bcl-2- 1. . . ,2000. 199 . -  
 , 2. . . . . -  
 , 99M - .2002. 1. . 114-121. -  
 Bcl-2, 3. . . . . -  
 [3,6,14,18]. , -

4. ?  
2010. 5. 71-77.

5. 2008. 3. 86-93.

6. 2006. 1. 70.

7. 6. 32-36. 1998.

8. 22. 4. 97-105. 2011.

9. 2010. 1. 23-25.

10. NF-κ 2012. 46. 3. 452.

11. 2011. 4. 64-68.

3. 22-25. 2005.

12. 2005. 25. 3. 37-40.

13. 2008. 3. 86-93.

14. 2009.

15. 72-78. 2011. 2.

16. 2012. 3. 28-33.

17. 2009.

18. Dobrodeev A.Yu., Zav'yalov A.A., Musabaeva L.I., Tuzikov S.A., Miller S.V., Smyshlyaeva E.A. Results of the patients of the combined treatment of non-small cell lung cancer with intraoperative radioterapy and cysplatinum. 2004. 49. 6. 64-70.

19. Musabaeva L.I., Lisin V.A., Zheravin A.A., Anisenya I.I., Bupalov V.I., Kol'chuzhkin A.M., Cheryashkina G.A. Radiation therapy in patients with locomotooor system tumors after organ-preserving surgery with implants from titanium alloys. 2003. 48. 2. 56-62.

20.Spirina L.V., Yunusova N.V., Kondakova I.V., Kolomiets L.A., Koval V.D., Chernyshova A.L. ASSOCIATION OF GROWTH FACTORS, HIF-1 AND NF- B

EXPRESSION WITH PROTEASOMES IN ENDOMETRIAL CANCER. Molecular Biology Reports. 2012. . 39. 9. . 8655-8662.

**Шаншашвили Е.В.**

168

( , ( , - - (72%), (65%), (81%), (68%).

**SUMMARY**

hormonal and energetic status was studied in 168 patients with endometrial hyperplasia and endometrial cancer. The comparative analysis of hormonal status (LH, FSH, estrogen, progesterone, testosterone, prolactin, SHBG), energetic status (leptin, grelin, insulin) and the assessment of lipid and carbohydrate metabolisms were carried out for patients with proliferative processes in the endometrium with the evidence of metabolic syndrome and without it. The study showed that the changes in hormonal status were characterized by a high frequency of disturbances with development of hyperestrogenemia (72%), hypertestosteronemia (65%), hyperinsulinemia (81%) and hyperleptinemia (68%). Moreover, the LH level and LH/FSH index were increased and FSH and progesterone levels were decreased. Significant changes in both carbohydrate (hyperinsulinemia, insulin resistance) and lipid (hypercholesterolemia, hypertriglyceridemia) metabolisms were revealed. Mechanisms of hormonal correlations which underlie pathological endometrial process were suggested. Further investigations are required to individually prognosticate endometrial cancer process and to form the groups at high risk for endometrial cancer based on the assessment of hormonal and energetic balances, as well as to correct properly metabolic disorders in patients with endometrial hyperplasia and endometrial cancer.

Key words: endometrium, hyperinsulinemia, insulin resistance, leptin, hormonal balance, energetic balance.

[4,10, ( ) [1,2,19]. 20 12,13]. - 2 - 28,5 100 - [3,6,8,15]. : ( - 168 - , ), .

	88	-		(	-
		-	, -	) [11,17,18].	
80		-		,	
	1 2	-			-
2	:	-		,	-
	(1 2)	(1 2).	,	,	,
		-		,	,
54,21±0,89		52,12±0,64		,	-
		« »			
	57				
	36,8+0,45	\ , I	- 31	[12,13,16].	
		- 27,5+21 \ .			
2	39,1+0,78,	2	-	1.	-
25,9+0,54			-	∴ , 2000. 199 .	
			-	2.	
			-	∴ ,	
			-	99M -	
			-	. 2002. 1. . 114-121.	
(	, -	)	-	3.	
)		(	-	∴	
			-		
			-	?	
			-	. 2010. 5. . 71-77.	
			-	4.	
			-	∴	
			-		
71%,	65%,	58%	,	5.	. 2008. 3. . 86-93.
/		SHBG	,	∴	
			-		
			-	. 2006. 1. . 70.	
	2,5			6.	
			-	∴	
			-		
2	,		-	. 1998. 6. . 32-36.	
			-	7.	
			-	∴	
			-		
			-	«	».
			-	. 2011. .	
		[5,7,9,14].		22. 4. . 97-105.	
			-	8.	
			-	∴	
			-	∴	
			-	∴	



4. . 2010. 1. . 23-25

NF-κ

9. . 2012. . 46. 3. . 452.

10. . 2011. 4. . 64-68.

11. 3. . 22-25.

12. 2005. . 25. 3. . 37-40.

13. . 2009

72-78. . 2011. 2. .

14. . . . .

15. . 2012. 3. . 28-33.

" . , 2009

16. . . . .

. 2012. 3. . 16-24.

17. Dobrodeev A. Yu., Zav'yalov A.A., Musabaeva L.I., Tuzikov S.A., Miller S.V., Smyshlyaeva E.A. Results of the patients of the combined treatment of non-small cell lung cancer with intraoperative radioterapy and cysplatinum. . 2004. . 49. 6. . 64-70.

18. Musabaeva L.I., Lisin V.A., Zheravin A.A., Anisenya I.I., Bupalov V.I., Kol'chuzhkin A.M., Cheryashkina G.A. Radiation therapy in patients with locomotooor system tumors after organ-preserving surgery with implants from titanium alloys. . 2003. . 48. 2. . 56-62.

19. Spirina L.V., Yunusova N.V., Kondakova I.V., Kolomiets L.A., Koval V.D., Chernyshova A.L. ASSOCIATION OF GROWTH FACTORS, HIF-1 AND NF- B EXPRESSION WITH PROTEASOMES IN ENDOMETRIAL CANCER. Molecular Biology Reports. 2012. . 39. 9. . 8655-8662.

***Шаншавили Е.В.***

**SUMMERY**

*the integrated study of the level of hormones in systemic circulation, estrogen reception and metabolism in patients with endometrial hyperplasia and endometrial cancer has shown that the urinary level of estrogen metabolites in patients with hyperplastic and malignant endometrium depends on the level of steroid hormones in systemic circulation. The study showed that the changes in hormonal status were characterized by a high frequency of disturbances with development of hyperestrogenemia, hypertestosteronemia. Moreover, the LH level and LH/FSH index were increased and FSH and progesterone levels were decreased. Correlation between the level of steroid hormone receptors and the level of estrogen metabolites has been identified. It confirms the theory of "estrogen" stimulation recommended for patients with proliferative endometrium*

*Keywords: endometrium, cancer, hormones, receptors, metabolites.*

«Excel 2000», «Statistica 6.0».

» [2,11].

», ( ),

( ),

52,12±0,64 50,21±0,89 ,

49,31±1,24

81%, – 32%.

88 , 65%, 71%,

32 58%, / , SHBG

36 ,

20 (53,5%)

ER (101-200 ), (51-100

) ( 200 )

( ) (17,8%).

( )

ER

(33%).

(100%),

(68%).



14. . . . . - 18. Dobrodeev A.Yu., Zav'yalov A.A., Musabaeva L.I., Tuzikov S.A., Miller S.V., Smyshlyaeva E.A. Results of the patients of the combined treatment of non-small cell lung cancer with intraoperative radioterapy and cysplatinum. - . 2004. . 49. 6. . 64-70.

15. . . . . 2011. 2. . 19. Musabaeva L.I., Lisin V.A., Zheravin A.A., Anisenya I.I., Bepalov V.I., Kol'chuzhkin A.M., Cheryashkina G.A. Radiation therapy in patients with locomotooor system tumors after organ-preserving surgery with implants from titanium alloys. - . 2003. . 48. 2. . 56-62.

16. . . . . 2012. 3. . 28-33. 20. Spirina L.V., Yunusova N.V., Kondakova I.V., Kolomiets L.A., Koval V.D., Chernyshova A.L. ASSOCIATION OF GROWTH FACTORS, HIF-1 AND NF- B EXPRESSION WITH PROTEASOMES IN ENDOMETRIAL CANCER. Molecular Biology Reports. 2012. . 39. 9. . 8655-8662.

17. . . . . , 2009 . . . . . : . 2012. 3. . 16-24.

**Эйберман А. <sup>1</sup>, Черненко Ю.В. <sup>2</sup>, Пиваковский Ю.М. <sup>3</sup>, Воротникова Н.А. <sup>4</sup>**

1  
2  
3  
4

THE SUMMARY

The article discusses the use of sour-milk mixtures for babies in the first year of life who are bottle-fed. Particular attention is paid to the analysis of breastfeeding babies in the first year of life, ways of influencing bowel definition intestinal microbiota of indications to administers fermented mixtures and their composition. Study of

influence of fermented milk mixture on the functional State of the digestive and intestinal microbiota when you include them in meals for children 1 year of life. Monitoring and General clinical, microbiological examination of gastroenterological and 32 children who for various reasons on artificial feeding, which was introduced into the diet of fermented milk mixture "Bellakt", highlighted the positive impact of the product functional nutrition on intestinal microbiota and gastroenterological pathology of children in the first year of life.

Key words: children of the first year of life, sour milk mixture, probiotics, intestinal microbiota.

46% 2010 [4].

( 1-2 ) 6 [3,5,7].

« »

(European Society of Paediatric Gastroenterology, Hepatology and Nutrition — ESPGHAN)

[6]: 1)

; 2) [3].

; 3)

( , D, , , , , )

- 1,4 1,5 100

[2].

Bifidobacteria lactis BB-12 1,3 105 (71,8%) 700  
 / . 1984 . 2002  
 GRAS (Generally Regarded As Safe), IgA-  
 (4 (4 )).  
 2 .  
 [1,8].  
 32 , 14 (43,8%)  
 , 20 (62,5%) 11  
 1-  
 2 3 9 (32%).  
 Esherichia coli  
 2  
 «  
 ».  
 4  
 6 . - 17 : 6 . - 15 ,  
 ( , , ,  
 ). 2500 4000 // . - 2012. - 13. - .77-87.  
 ,, - 49 54 : - 2009. 332. -  
 11,  
 - 6, - 3 - 2, -  
 ;5 // . - 2012. - 91(6). -  
 .95-100.

---

4.

//

5.

. - 2011. - 68 .

.86-90.

. - 2004. - 2(3) - //



## Биологические науки

*Аникина Н.Ю., Подоплекин А.Н.*

### **SUMMARY**

*During adaptation to low temperatures in the human body functional changes occur that require hard work of the brain with a significant energy cost. Research of constant potentials revealed increased brain metabolism among foreign students while simultaneously enhancing the activity of subcortical structures. Students-northerners tend to have higher values of the level of constant potentials in the parietal cortex during local cooling, which may be indicative of the generated adaptation to cold impact. In both groups showed involvement in the mechanisms of cold adaptation occipital areas of the brain. The data indicate the greater adaptability to cold impact of students-northerners body.*

*Keywords: foreign students, North, cold adaptation, the level of constant potentials of the brain*

[1,2,5].

[2,7].

« - ».

5-7

( )

(t=4-60 )

5-

[4,8,10].

“SPSS 20 for Windows”.

18 21 ,

t-

U

(

),

Mauchly.

( )

0,05.

172

91

-81

( .1).

12-

1

	(n=91)	(n=81)	
Fpz	17,94(15,33;20,56)	12,97(10,07;15,89)	0,012
Fd	13,07(9,83;16,31)	10,18(4,18;16,2)	0,349
Fs	13,75(10,76;16,73)	7,97(1,42;14,52)	0,108
Cd	16,32(13,09;19,56)	13,62(8,12;18)	0,104
Cz	22,44(20,25;24,64)	17,27(14,9;19,64)	0,002
Cs	16,28(12,53;20,04)	11,41(6,61;16,22)	0,043
Pd	16,78(13,67;19,9)	13,84(8,07;19,61)	0,069
Pz	16,72(13,45;19,99)	13,35(8,21;18,49)	0,247
Ps	17,52(14,33;20,71)	12,96(7,76;18,17)	0,053
Oz	18,92(16,55;21,3)	13,999(11,41;16,59)	0,006
Td	16,57(14,3;18,85)	11,4(9,06;13,75)	0,002
Ts	15,09(12,97;17,21)	11,88(9,26;14,5)	0,058

95%

Fpz (p=0.012),

Cz (p=0.002),  
Td (p=0.002).

Oz (p=0.006)

[4,5].

« »

[11],

[7,9].

Td Ts). ( <0,05) (Fpz, Cz, Oz, Td, Ts )  
( .2).

2

	(n=91)			(n=81)		
Fpz	17,94(15,33;20,56)	19,7(16,78;22,63)	0,011	12,97(10,07;15,89)	14,59(11,55;17,63)	0
Fd	13,07(9,83;16,31)	13,25(10,04;16,45)	1	10,18(4,18;16,2)	11,21(5,14;17,28)	0,428
Fs	13,75(10,76;16,73)	14,16(11,2;17,13)	1	7,97(1,42;14,52)	8,88(2,52;15,24)	1
Cd	16,32(13,09;19,56)	16,63(13,48;19,79)	1	13,62(8,12;18)	14,23(9,16;19,31)	0,098
Cz	22,44(20,25;24,64)	23,85(21,35;26,35)	0,032	17,27(14,9;19,64)	18,4(16;20,79)	0,003
Cs	16,28(12,53;20,04)	16,68(13,01;20,34)	1	11,41(6,61;16,22)	12,589(7,66;17,52)	0,121
Pd	16,78(13,67;19,9)	17,34(14,26;20,42)	1	13,84(8,07;19,61)	15,44(9,63;21,25)	0,013
Pz	16,72(13,45;19,99)	16,9(13,73;20,07)	1	13,35(8,21;18,49)	14,57(9,37;19,77)	0,155
Ps	17,52(14,33;20,71)	17,78(14,64;20,92)	1	12,96(7,76;18,17)	14,45(9,09;19,81)	0,04
Oz	18,92(16,55;21,3)	20,49(17,94;23,04)	0,007	13,999(11,41;16,59)	15,46(12,82;18,09)	0,001
Td	16,57(14,3;18,85)	17,95(15,36;20,54)	0,046	11,4(9,06;13,75)	12,59(10,2;14,97)	0,005
Ts	15,09(12,97;17,21)	16,74(14,26;19,21)	0,011	11,88(9,26;14,5)	13,42(10,7;16,14)	0

95%

Ps Pd [6].

[6].



[2,6].

-

-

(Fpz, Cz, Oz, Ts)

(.3).

3

	(n=91)			(n=81)		
Fpz	17,94(15,33;20,56)	19,43(16,64;22,23)	0,265	12,97(10,07;15,89)	15,1(12,27;17,94)	0
Fd	13,07(9,83;16,31)	13,75(10,34;17,16)	1	10,18(4,18;16,2)	13,16(7,02;19,3)	0,683
Fs	13,75(10,76;16,73)	14,77(11,61;17,94)	1	7,97(1,42;14,52)	10,65(4,4;16,9)	1
Cd	16,32(13,09;19,56)	17,13(14,06;20,2)	1	13,62(8,12;18)	16,02(11,35;20,7)	0,455
Cz	22,44(20,25;24,64)	23,58(21,31;25,85)	0,715	17,27(14,9;19,64)	19,46(17,25;21,68)	0,002
Cs	16,28(12,53;20,04)	17,38(14;20,77)	1	11,41(6,61;16,22)	14,56(9,7;19,42)	0,433
Pd	16,78(13,67;19,9)	18,47(15,25;21,69)	0,984	13,84(8,07;19,61)	17,99(12,83;23,14)	0,057
Pz	16,72(13,45;19,99)	17,8(14,81;20,78)	1	13,35(8,21;18,49)	16,91(11,9;21,92)	0,199
Ps	17,52(14,33;20,71)	18,24(15,17;21,32)	1	12,96(7,76;18,17)	17,09(11,91;22,28)	0,096
Oz	18,92(16,55;21,3)	19,69(17,44;21,94)	1	13,999(11,41;16,59)	16,49(14,05;18,93)	0,001
Td	16,57(14,3;18,85)	17,15(14,63;19,67)	1	11,4(9,06;13,75)	12,89(10,59;15,18)	0,074
Ts	15,09(12,97;17,21)	15,75(13,48;18,02)	1	11,88(9,26;14,5)	14,05(11,53;16,57)	0,003

95%

-

[7,10].

Oz.

-

1.

-

-

, 2009. .24–26.

-

2.

-

-

//

. 2014. . 5. .9–16

-

3.

-

-

//  
. 2001. .27, 1. .140–

-

141.

5-

4.

-

-

-

//  
. 2009. . 6, .35. .43–

-

48.

5.

-



- 20–25. // . 2014. 2. . « – 03» // . 2005. 1. . 44–46.
6. . . . 9. // . 2001. . 27, 1. . 127–2008. 8. . 32–33.
133. 7. . . . 10. . . . , 2003, 288 .
2. . 148–153. // . 2004. 11. . . . .
8. . . . . // . 2011. . 5, 1. . 5–19.

**Гаврилькова Е. А.<sup>1</sup>, Додонова А. Ш.<sup>2</sup>**

<sup>1</sup> . ,  
<sup>2</sup> . . . ,

**METHODS OF RHAPONTICUM CARTHAMOIDES SEED STORAGE**

Gavrilkova Elena Anatolyevna, Senior lecturer of State University of Karaganda. Karaganda

Dodonova Alexandra Shavkatovna, Candidate's degree in Biological sciences, Associate professor of State University of Karaganda, Karaganda

*Rhaponticum carthamoides*,

3, 6 12 .

**ABSTRACT**

*In this article we have reviewed the conditions and methods of Rhaponticum carthamoides seed storage, that is drug endemic plant. the degree of preservation of viability was studied for germination and intergrowth energy. Seed was stored in different tare and with different temperature for 3, 6 and 12 months. Also we researched preservation of Rhaponticum carthamoides seed's viability after crioconservation in different tare and with different methods of thawing. Room temperature and paper tare were found the best conditions for Rhaponticum carthamoides seed's durable conservation. However, inspite of lower rates of preservation of viability with crioconservation, this method shall not be neglected, because it let us keep material unchanged for decades.*

*: Rhaponticum carthamoides; ; ; .*

**Keywords:** *Rhaponticum carthamoides, seed; terms of storage; crioconservation.*

), ( [2], [3].

2- 4-

0,5% KMnO<sub>4</sub>.

+24

(*Rhaphanistrum carthamoides* Willd., Asteraceae) -

30

90°

[4, 5].


[6].

[1] 10±0,2%.

( « » « -18°

1 3

40±0,3% 39,9±0,5% 30% ( 1).



1. *Rhaphanistrum carthamoides*

-20-22 °C, -18 °C, -196 °C ;

3, 6, 12



*Rhaphanistrum*

carthamoides, 3, 6, 12 - , , -  
 - , -  
 - , -  
 53,7±0,8%. , - ( 1, 2).  
 ,

1

Rhap nticum carthamoides,

	, %			, %		
	3	6	12	3	6	12
	30±0,4	40±0,8	20±0,5	28,7±0,5	43,6±0,7	20±0,4
	37,5±0,7	20±0,5	25±0,6	24,8±0,6	20±0,9	25±0,7
	33±0,4	33±0,7	57,1±0,7	32,3±0,5	32±0,7	53,7±0,8
	50±0,6	33±0,5	28,57±0,4	26,2±0,7	29,9±0,5	34,57±0,7



2. ( ) ( ) Rhap nticum carthamoides,

43,6% 6 , - , -  
 12 , , -  
 20%. ,

37,5%.

- 50%,

( 2, 3).

6 (-18 ),

56,3% 12 3 25%

12,5%.

Rhap nticum



- 55,5% carthamoides,

12

Rhap nticum carthamoides,


+4°

	, %			, %		
	3	6	12	3	6	12
		25±0,7	25±0,4	50±0,5	23,4±0,7	25±0,4
	50±0,3	20±0,7	37,5±0,7	40,6±0,4	20±0,7	37,5±0,9
	12,5±0,7	60±0,4	12,5±0,5	19,7±0,7	56,3±0,8	12,5±0,8
	50±0,4	60±0,7	37,5±0,7	45,3±0,5	55,5±0,7	37,5±0,7



3. ( ) ( ) Rhap nticum carthamoides, +4°

( 4).



4. Rhamnus cathartica

35±0,7%.  
 25±0,2%.  
 20±0,3%.  
 Rhamnus cathartica  
 16%, 15- // /  
 , 1976. - . 75-85.  
 3.  
 4. , 1950. - 56 .  
 Rhamnus cathartica.  
 : .... : 03.00.32:  
 , 2004 150 с. , 61:04-  
 3/1495.  
 5.  
 Pyrus L. // . - 2004. - 46  
 (10). - . 851.  
 6.  
 . - - : , 1976.- 45 .

**Крылова А. .**

**ABSTRACT**

*The problem of stabilizing the contact implant-bone tissue in osseointegration has attracted the interests of many researchers. Osseointegration is a complex multi-component process is provided molecular structures. Therefore it is very important to understand the interaction of these structures in a single system and to provide a processes, effected bone formation. So many studies are devoted to the development of a database of proteins belonging to a particular process of osseointegration in the analysis of the interactions to ensure the stability of the implant-bone interface.*

*Key words: osseointegration, dental implant, databases, osteoblast, bone tissue.*

[3].

[2].

» [6].

[7, 12].

[8]. PubMed, PubMedCentral, PDB, GeneBank, (Elibrary), 10- [10, 11]. [9, 13], [5, 14, 15] [4]. Protein – Name – Gene – Processes – Synthesis of extracellular matrix – Differentiation and proliferation – Remodeling – Resorption – +++ - ++ - +- -

Protein Name	Gene	Synthesis of extracellular matrix	Processes
--------------	------	-----------------------------------	-----------



Protein		Processes			
Name	Gene	Synthesis of extracellular matrix	Differentiation and proliferation	Remodeling	Resorption
(TGF- )	tgfb1	-	+++	++	-
( -2, -5, -7)	bmp2 bmp5 bmp7	+++	+++	++	-
I	il1b il1a	-	+	-	-
-9 -8	mmp9 mmp8	-	-	+++	+++
	fga fgb fgg	-	+++	++	-
	fn1	++	+++	+	-
I II III V  I I XXIV	colla1 colla2 col2a1 col3a1 col5a1  col5a2  col5a3 ol11a 1 ol9a1 col24a 1	+++	+++	+++	-
E2	ptger2	-	-	-	+++

[12].

[7].

1. ... , 2010; 5:4-8.
2. ... IV , 2013; 201-202.
3. ... 2:30-35.
4. ... 11: . 2012; 2:4-10.
5. ... ( . 2012; 4(66):126-134.
6. ... 2014; 3:54-57.
7. Bell B. F., Schuler M., Tosatti S., Textor M., Schwartz Z., Boyan B. D. Osteoblast response to titanium surfaces functionalized with extracellular matrix peptide biomimetics. Clin. Oral. Implants Res. 2011; 22(8):865–872.
8. Chung E.H., Gilbert M., Viridi A.S., et al. Biomimetic artificial ECMs stimulate bone regeneration. J. Biomed. Mater. Res. A. 2006; Vol. 79:815-826.
9. Hennessy K.M., Clem W.C., Phipps M.C., Sawyer A.A., Shaikh F.M., Bellis S.L. The effect of RGD peptides on osseointegration of hydroxyapatite biomaterials. Biomaterials. 2008; 29(21): 3075–3083.
10. Maciel J., Oliveira M.I., Colton E., McNally A. K., Oliveira C., Anderson J. M., Barbosa M. A. Adsorbed Fibrinogen Enhances Production of Bone- and Angiogenic-Related Factors by Monocytes/Macrophages. Tissue Eng. Part A. 2014; 20(1-2):250–263.
11. Mountziaris P.M., Mikos A.G. Modulation of the inflammatory response for enhanced bone tissue regeneration. Tissue Eng. Part B Rev. 2008; 14: 179-86.
12. Nishimura I. Genetic Networks in Osseointegration. J. Dent. Res. 2013; 92(12 Suppl): 109S–118S.
13. Razzaque M.S. The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis. Nature Reviews Endocrinology 2009; 5(11):611–9.
14. Stanford C.M. Surface modification of biomedical and dental implants and the processes of inflammation wound healing and bone formation. Int. J. Mol. Sci. 2010; 11(1):354–369.
15. Turkyilmaz I., Sennerby L., McGlumphy E.A., Tozum T.F. Biomechanical aspects of primary implant stability: a Human cadaver study. Clin. Implant Dent. Rel. Res. 2009; Vol. 11:113–119.

**Кусакина Е.В.**

«

»

( Siphonaptera)

2000

[1].

( )

3—5

« »

20

[2].

1 20—

30 1—3 50—60 10—15 20—25 ;

12—13 / ), (

900 2— : 1200 2

( . *Mus musculus*) —

[3].

norvegicus) — ( . Rattus  
: ,  
Rattus norvegicus — ,  
— ( )  
: (John Berkenhout, 1769 )  
1728 , «  
».  
, ,  
, ,  
, NTSYS.  
, — , 2000.  
2000 2, (2013-  
2015)  
20 ,  
, ,  
— « 6 ,  
».  
, ,  
10 / ,  
80 ( « » « ».  
1 ). 8 17 « »  
72 ) , « »  
[1].  
« ( ,  
» )  
2013- ( )  
2015 . [4].

1

	-		-		-		-		-	
	78	8	81	5	94	7	77	5	330	25
	58	4	63	6	83	7	85	8	289	25

2

	43	2	4	49
	65	7	1	73
	54	1	3	58
	68	6	2	76



3

/			
1	Megabothris calcarifer (Wagner.1913)	1	1
2	Monopsyllus anisus (Rothschild. 1907)	2	5
3	Nonopsyllus fasciatus (Bosc.1801)	2	5
4	Leptopsylla segnis (Schocher.1811)	5	2


: 1 5- ; 2- ; 1- ; 5- ; 4- ; 3-

4 - 2015 . .  
2013- .





2013-2015 . .



1.

2.

3.

4.

5.

6. - - - - - ,1985. .228-231. -  
 - - - - - 2. - - - - - - - - - - -  
 , - - - - - ,1941.116 . - - - - -  
 3. - - - - - - - - - - -  
 7. // - - - - -  
 , 1965. - - - - -  
 5. .161 - - - - -  
 4. - - - - - // -  
 ,1960. .29, .5. - - - - -  
 1. - - - - - .688-689. - - - - -  
 // - - - - -

**Омиадзе Н.Т.<sup>1</sup>, Мchedlishvili Н.И.<sup>2</sup>, Абутидзе М.О.<sup>3</sup>**

*Omiadze N.T., Mchedlishvili N.I., Abutidze M.T.*  
**BLUEBERRY FRUITS AS A RAW MATERIAL FOR PRODUCING NATURAL FOOD RED COLORANT**  
*Durmishidze Institute of Biochemistry and Biotechnology of Agricultural University of Georgia*  
**ABSTRACT**

*The interest of the food industry in natural colorants has increased significantly over the last years. The purpose of this work was to determine the content of phenolic and red coloring compounds in blueberry fruit and its alcoholic extract, as well as to test antioxidant activities of these samples, in order to use blueberry fruits as a raw material for producing red food colorant. Blueberry fruits were found to contain quite a large amount of red coloring compounds (3%) and phenolic compounds (8%). Antioxidant activity of blueberry fruits and their alcoholic extract was equal to 0.54 [Fe2+] and 0,37 mmol of 1g/l sample respectively. The quantity of red coloring compounds in the alcoholic extract decreased significantly during the storage for a year. Thus, according to the content of red coloring compounds blueberry fruits are a potential source for producing natural food red colorant though blueberry fruit red pigments are unstable during the storage and needs stabilizing.*

*Keywords: Natural colorants, red pigments, anthocyanins, blueberry*

*(Vaccinium myrtillus)*

*(3%)*

*(8%).*

*0,54 [Fe2 +] 0,37 1 /*



	/	%	/	%	Fe <sup>2+</sup>	%
	32,40±0,00	100±0,0	7,76±0,00	100±0,00	0,540±0,00	100±0,00
	30,86±0,00	95,25±0,00	3,20±0,00	41,3±0,00	0,369±0,00	67,4±0,00

70%-  
40%  
95%  
70%

	, %	, /	, %	Fe <sup>2+</sup>
( )	32,40±0,00	100±0,00	7,76±0,00	100±0,00
( )	30,86±0,00	95,25±0,00	3,20±0,00	41,3±0,00

1. " , , 2009
2. Benzie F. F., Strain J. J. The Ferric reducing ability of plasma (FRAP) as a measure of 'Antioxidant Power': The FRAP assay. Anal. Biochem. 1996; 239:70-76.
3. Chattopadhyay P., Chatterjee S., Sen SK. Biotechnological potential of natural food grade biocolorant. Afr. J. Biotechnol. 2008; 7 (17):2972-2985.
4. Griffiths J.C. Coloring food and beverages. Food Techno. 2005; 59 (5): 38-44.

5. Niir Board. The Complete book on Natural Dyes & Pigments, Asia Pacific Business Press Inc. 2005, 448p oxidation substrates and antioxidants by means of Folin-Ciocalteu reagent. Meth. Enzymol. 1999; 299: 152-178.
6. Singleton VL, Orthofer R, Lamuela-Raventos RM. Analysis of total phenols and other

**Белицкая Л.А.<sup>1</sup>, Сонкин В.Д.<sup>2</sup>, Акимов Е.Б.<sup>3</sup>**

1

2

3

**POSSIBLE MECHANISMS OF HEALTH EFFECTS OF EXERCISE ON METABOLIC PROCESSES IN HUMAN BODY**

*Belitskaya LA Sonkin VD, Akimov EB*

*Department of Physiology RGUFKSMiT, Moscow, Russia*

*FGBUN "Institute of Developmental Physiology, Russian", Moscow, Russia*

*Keywords: brown adipose tissue; irisin hormone; Blood lactate; metabolic processes; homeostasis.*

**ABSTRACT**

*The review of modern foreign and domestic literature reviewed non-shivering thermogenesis role in maintaining of the homeostasis of the human body, and more specifically - the specificity and metabolic function of brown adipose tissue, which has recently been found not only in children but also in healthy adults. According to the analysis of literature hypothesis explaining health benefits of exercise by activating the production of muscle cytokines that promote redifferentiation processes of white fat cells into the "beige", having increased oxidative potential and contribute to the maintenance of the body's carbohydrate and lipid homeostasis. The essential point - the optional presence of brown adipose tissue, as well as optional features implemented by it, in contrast to other structures of the body with more than an unambiguous meaning. Conversion of fat tissue under the influence of exercise are much more complex picture than the mechanical application of caloric approach to exercise for an explanation of their health effects. It is likely that the efficiency of recovery, at least in some subjects, will increase the combined effects of exercise and cold exposure. The hypothesis needs further experimental verification.*

2 21 - 16 ( )

(1516–1565). ( )

« » - « » [3].

( ).

40 ( - 70-

[16,23,34,35,47,48],


[2,5].

« - :

» ( .1).

10

[13].



- 1. Жировой пузырек
- 2. Ядро клетки
- 3. Митохондрии
- 4. Оболочка клетки

. 1 ( ) ( )

21 ( )

[28,30].

10 [20, 46].

[19,26,37,45,46]. - 20 95%.

( - 200 )

[19,45, 49].

	<p style="text-align: right;">- - - ( )</p> <p style="text-align: right;">- - -</p> <p style="text-align: right;">WAT - BAT -</p> <p style="text-align: right;">UCP1 -</p>
--	--

. 2

( : [20])

70- [9].

3), ( , « »,

[29].

5 6) UCP  
(uncoupling protein= ),

1. UCP1 [11,21,27,32].

. 3

[19,29].

[12,29,40].

«





« »

[45].

1

(200-250 / )

40


« » [4,33,44].

( .5)

[50].

[10].

[1].



.5

( ) .

[1, 4]. -  
1 , (0° ), -  
1,5- , - ) , -  
, -  
( 1,5-2 ) , -  
1 . , -  
- . 2 , -  
[26].  
[25], - « -  
, » -  
MCT1 – , [1, 6, 42]. , -  
, 1 , -  
, , -  
[17, 31]. , -  
, -  
- -  
[6]. -  
, [14, 18, 33], -  
( ) , - , -  
, -  
: - , -  
- [42]. , -  
- , -  
, « » -  
, [36]. -  
- [7], 6  
[22].

1. ... ..  
 ... ..  
 ..  
 .. //  
 , 2010, 36, 4  
 2. ...  
 .. , 1979. - 156  
 3. ... ..  
 //  
 , 2002, 33, 2. - 17-29  
 4. ... ..  
 ..  
 //  
 2011.  
<http://phmag.imbp.ru/articles/Sonkin.pdf>  
 5. ... ..  
 // ..  
 .. , 1974. -  
 120-125
6. ... ..  
 ..  
 :  
 // .. , 2010, .  
 36, 5, .121-139  
 7. ... ..  
 , .. , ..  
 , .. «  
 ,  
 -  
 » // .. - 2014. -  
 4 - .78-90.  
 8. Acheson KJ, Ravussin E, Wahren J, Jéquier E. Thermic effect of glucose in man. Obligatory and facultative thermogenesis. // J Clin Invest. 1984; 74(5):1572-80.  
 9. Akhmerov R.N. Qualitative difference in mitochondria of endothermic and ectothermic animals. // FEBS Lett. 1986 Mar 31;198 (2):251-5.  
 10. Akimov E.B., Andreev R.S., Arkov V.V., Son'kin V.D., Tonevitskii A.G. Thermal "portrait" of sportsmen with different aerobic capacity // Acta Kinesiologiae Universitatis Tartuensis, 2009, v.14, pp.7-16  
 11. Andrews ZB, Diano S, Horvath TL. Mitochondrial uncoupling proteins in the CNS: in support of function and survival. // Nat Rev Neurosci. 2005 Nov;6(11):829-40.  
 12. Astrup A, Simonsen L, Bülow J, Madsen J, Christensen NJ. Epinephrine mediates facultative carbohydrate-induced thermogenesis in human skeletal muscle. // Am J Physiol. 1989 Sep;257(3 Pt 1):E340-5.  
 13. Avram AS, Avram MM, James WD. Subcutaneous fat in normal and diseased states: 2. Anatomy and physiology of white and brown adipose tissue. // J Am Acad Dermatol., 2005, v.53, #4, p.671  
 14. Booth J, Marino F, Ward JJ. Improved running performance in hot humid conditions following whole body precooling. Med Sci Sports Exerc. 1997 29(7):943  
 15. Boström P, Wu J, Jedrychowski MP, Korde A. A PGC1- -dependent myokine that drives brown-fat-like development of white fat and thermogenesis. // Nature. 2012 Jan 11; v.481(7382):p.463-8.  
 16. Brooks G.A. Anaerobic threshold: the review of the concept and directions for future research // Med.Sci.Sports Exerc.- 1985.- 17.- N 1.- P.22-31.

17. Brooks GA. Cell-cell and intracellular lactate shuttles. // *J Physiol*. 2009.- v. 587(Pt 23):p.5591-600
18. Buchheit M, Peiffer JJ, Abbiss CR, Laursen PB. Effect of cold water immersion on postexercise parasympathetic reactivation. // *Am J Physiol Heart Circ Physiol*. 2009 Feb;296(2):H421
19. Cannon B., and Nedergaard J. Brown Adipose Tissue: Function and Physiological Significance. // *Physiol Rev* 2004 v.84: p.277–359
20. Chiba S, Katsuragi I, Simada T, Adachi I, et al. Evaluation of human brown adipose tissue using positron emission tomography, computerised tomography and histochemical studies in association with body mass index, visceral fat accumulation and insulin resistance. *Obes Rev* 7, 2006; Suppl 2: 87.
21. Cioffi F, Senese R, de Lange P et al. Uncoupling proteins: a complex journey to function discovery. // *Biofactors.*, 2009, v.35, #5, p.417
22. Cypess A.M., Lehman S., Williams G., et al. Identification and Importance of Brown Adipose Tissue in Adult Humans // *The New England Journal of Medicine*, 2009. – V. 360, N15.- pp. 1509-1517
23. Davis I.A. Anaerobic threshold: review of the concept and directions for future research // *Med. Sci. Sport Exerc.*- 1985. -V. 17. - 1.-P. 9-18
24. Dawkins MJ, Scopes JW. Non-shivering thermogenesis and brown adipose tissue in the human new-born infant. // *Nature*. 1965 v. 206 (980):201-2.
25. De Matteis R, Lucertini F, Guescini M, Polidori E, Zeppa S, Stocchi V, Cinti S, Cuppini R. Exercise as a new physiological stimulus for brown adipose tissue activity // *Nutr Metab Cardiovasc Dis*. 2013; v.23 (6): p.582-90.
26. Enerbäck S. Human brown adipose tissue. // *Cell Metab*. 2010; v.11(4):p.248-52.
27. Golozoubova V., Hohtola E., Matthias A., Jacobsson A., Cannon B., Nedergaard J. Only UCP1 can mediate adaptive nonshivering thermogenesis in the cold. *FASEB*, 2001, J 15: 2048–2050.
28. Hansen JC, Gilman AP, Odland JO. Is thermogenesis a significant causal factor in preventing the "globesity" epidemic? // *Med Hypotheses*. 2010; v.75(2): 250-6.
29. Himms-Hagen J. Brown adipose tissue thermogenesis: interdisciplinary studies. // *FASEB J.*, 1990, v. 4 (11), p.2890
30. Hubáček JA. Eat less and exercise more - is it really enough to knock down the obesity pandemic? // *Physiol Res*. 2009;58 Suppl 1:S1-6.
31. Iwanaga T, Kuchiiwa T, Saito M. Histochemical demonstration of monocarboxylate transporters in mouse brown adipose tissue. // *Biomed Res*. 2009. v.30(4):p.217-25.
32. Klingenspor M, Fromme T, Hughes DA Jr, et al. An ancient look at UCP1. // *Biochim Biophys Acta*. 2008, v.1777 (7-8):p.637-41.
33. Lee P., Swarbrick M.M., and Ho K.K.Y. Brown Adipose Tissue in Adult Humans: A Metabolic Renaissance // *Endocr Rev*. 2013; v.34(3): p.413-38..
34. Mader A., Heck H. A theory of the metabolic origin of "Anaerobic threshold" // *Int. J. Sports Med.*- 1986.-7.- Suppl. - P.45-65.
35. Mahon A.D., Cheatham C.C. Ventilatory Threshold in Children: A Review // *Pediatric Exercise Science*, 2002, v.14, p. 16-29
36. Moreno-Navarrete JM, Ortega F, Serrano M. Irisin Is Expressed and Produced by Human Muscle and Adipose Tissue in Association With Obesity and Insulin Resistance // *J Clin Endocrinol Metab.*, 2013; v.98(4): E769-78
37. Nedergaard J, Bengtsson T, Cannon B. Unexpected evidence for active brown adipose tissue in adult humans. // *Am J Physiol Endocrinol Metab*, 2007. v. 293: p. E444–E452.
38. Nedergaard J, Cannon B. The changed metabolic world with human brown adipose tissue: therapeutic visions. // *Cell Metab*. 2010 Apr 7;11(4):268-72.
39. Rose G, Crocco P, De Rango F, Montesanto A, Passarino G (2011) Further Support to the Uncoupling-to-Survive Theory: The Genetic Variation of Human UCP Genes Is Associated with Longevity. *PLoS ONE* 6(12): e29650.
40. Seydoux J & Girardier L. Control of brown fat thermogenesis by the sympathetic nervous system. // *EXS*, 1978. v.32, p.153–167.
41. Sharp LZ, Shinoda K, Ohno H, Scheel DW, Tomoda E, Ruiz L, Hu H, Wang L, Pavlova Z, Gilsanz V, Kajimura S. Human BAT possesses molecular signatures that resemble beige/brite cells // *PLoS One*. 2012; vol.7(11): e49452.

42. Son'kin VD., EB. Akimov, RS. Andreev, AV. Yakushkin and AV. Kozlov Brown Adipose Tissue Participate in Lactate Utilization during Muscular Work //icSPORTS 2014. Proceedings of the 2nd International Congress on Sports Sciences Research and Technology Support – .97-102.
43. Symonds ME, Henderson K, Elvidge L. Thermal Imaging to Assess Age-Related Changes of Skin Temperature within the Supraclavicular Region Co-Locating with Brown Adipose Tissue in Healthy Children. // J Pediatr. 2012; v.161(5): 892-8.
44. van der Lans AA, Wierts R, Vosselman MJ, Schrauwen P, Brans B, van Marken Lichtenbelt WD. Cold-activated brown adipose tissue in human adults: methodological issues. // Am J Physiol Regul Integr Comp Physiol., 2014, v 307, #2: R103-13.
45. Van Marken Lichtenbelt W.D., Vanhommerig J.W., Smulders N.M. Cold-Activated Brown Adipose Tissue in Healthy Men // The New England Journal of Medicine, 2009. – V. 360, N18.- pp. 1500-1508
46. Virtanen K.A., Lidell M.E., Orava J. Functional Brown Adipose Tissue in Healthy Adults // The New England Journal of Medicine, 2009. – V. 360, N18.- pp. 1518-1525
47. Wasserman K., Whipp B.J., Koyal S.N, Beaver W.L. Anaerobic threshold and respiratory gas-exchange during exercise // J. Appl. Physiol.- 1973.- 35.- N 2.- P.236-243.
48. Whipp BJ, Ward SA. The physiological basis of the 'anaerobic threshold' and implications for clinical cardiopulmonary exercise testing. // Anaesthesia. 2011 Nov; 66(11):1048-9;
49. Wijers S., Saris W., and van Marken L.W.D. Individual Thermogenic Responses to Mild Cold and Overfeeding Are Closely Related // The Journal of Clinical Endocrinology & Metabolism, 2007.
50. Wu J, Boström P, Sparks LM, Ye L. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. Cell (2012) v.150, 1–11

Уланова О. А., Долматова Л. .

( ) *Eupentacta fraudatrix*

(100 )

( 2 )

18

2,

2


#### SUMMARY

Variations in apoptosis level in phagocytes (P2) or morula cells (MC) of holothurian *Eupentacta fraudatrix* which were exposed to humoral products from each other preincubation medium were studied at presence (100 μM) or absence of dexamethasone. We show that humoral products from both P2 and MC cells induced apoptosis in target cells after 18 hours after exposure. Preincubation of producer cells with dexamethasone provoke modulation in humoral products effects in cell-cell interactions, increasing apoptosis level in MC cells and decreasing its level in P2 cells. This effect could be associated with the difference in sensitivity of MC and P2 to apoptosis-modulating


activity of dexamethasone. Our results show the difference in dexamethasone-induced immunocytes apoptosis and can be used for further investigation of their roles in *E. fraudatrix* immunereactions.

Keywords: Cell interaction, holothurian's immunity, apoptosis, dexamethasone.

[4] 1:2. -  
 , ( ) 40 -  
 ( ) -  
 [3]. - , 2,  
 , - -  
 , - [14]. [15]. - -  
 - 2  
 - ( . 1) -  
 - ( ) -  
 - 3 -  
 [1]. (100 ) -  
 - 2  
 , ( ( 2+Dex), ( +Dex))  
 ( 2, ).  
 [4].  
 Eupentacta fraudatrix (Echino-  
 dermata, Holothuroidea) -  
 ( 1- 2- (1  
 ) - /1 ) 2 1:1.  
 , , -  
 ( ) [6]. 1 - 18 (pH 7,6).  
 , 22° .  
 -  
 (Dex), , 1000g 5 -  
 [15], - 5° ,  
 [7]. - Hoechst 33342 [12]  
 2- -  
 300 g 15 5° -  
 -  
 - 8  
 E. fraudatrix ( ) -  
 , -  
 .  
 E. fraudatrix ( 35-70 ) ±  
 ) -  
 2008 . t ( -  
 INSTAT-3, GraphPad Software). -  
 -  
 P<0,05. -  
 , -  
 2  
 ( . 2).



. 1.



. 2.

( )  
 ( ).  
 18- 2 - Hoechst 33342 , -  
 ( +Dex) ( . 3, ). 18- 2 65% ( <0,001)  
 Hoechst 33342 ( . 3, ), ( 2+Dex) , -  
 ( +Dex) 2,5 3,5 , ( . 4, ).  
 , 18- - 2 , -  
 , 2 2 , -  
 2 ( . 4, ). , -  
 18- 2 ( 2+Dex) - , -  
 ( . 4, ).

2.

2,


[2; 14; 13].

[1].

[15]


1 [15].

2



3. Hoechst 33342 ( )  
18  
: 1 - ; 2 -  
; 3 -

: \* <0,001



4. Hoechst 33342 ( )  
18  
: 1 - ; 2 -  
; 3 -

: \* <0,01; \*\* <0,001

(100 ) Kraaij et al. [8]

2,

T-

[8].

[9],

2

2.

- [10].
- p53 ( ) [5]
- bcl-2 [11].  
2-
- 2
- 2
1. . . . .  
. . . . .  
Asterias rubens.  
. 2005; 41(2):107-113.
2. . . . .  
. 1997; 117 (2):155-7.
3. . . . .  
. 1999; 1:17-24.
4. Chia F., Xing J. Echinoderm coelomocytes. Zoological Studies. 1996; 35(4):231-254.
5. Chiou S.K., Rao L., White E. Bcl-2 blocks p53-dependent apoptosis. Molecular and Cellular Biology. 1994; 14(4):2556-63.
6. Dolmatova L.S., Eliseykina M.G., Timchenko N.F., Kovaleva A.L., Shitkova O.A. Generation of reactive oxygen species in different fractions of the coelomocytes of holothurian Eupentacta fraudatrix in response to the thermostable toxin of Yersinia pseudotuberculosis in vitro. Chinese Journal of Oceanology and Limnology. 2003; 21(4):293-304.
7. Herold M.J., McPherson K.G., Reichardt H.M. Glucocorticoids in T cell apoptosis and function. Cellular and Molecular Life Sciences. 2006; 63:60-72.
8. Kraaij M.D., der Kooij S.W., Reinders M.E., Koekkoek K., Rabelink T.J., van Kooten C., Gelderman K.A. Dexamethasone increases ROS production and T cell suppressive capacity by anti-inflammatory macrophages. Molecular Immunology. 2011; 49: 549-557.
9. Lafont R., Mathieu M. Steroids in aquatic invertebrates. Ecotoxicology. 2007; 16:109-30.
10. Liles W.C., Dale D.C., Klebanoff S.J. Glucocorticoids inhibit apoptosis of human neutrophils. Blood. 1995; 86:3181-8.
11. Mann C.L., Hughes F.M., Cidlowski J.A. Delineation of the signaling pathways involved in glucocorticoid-induced and spontaneous apoptosis of rat thymocytes. Endocrinology. 2000; 141:528-38.
12. Pollack A., Ciancio G. Cell cycle phase specific analysis of cell viability using Hoechst 33342 and propidium iodide after Ethanol preservation. Methods in Cell Biology. 1990; 33:19-24.
13. Sabbione F., Gabelloni M.L., Ernst G., Gori M.S., Salamone G., Oleastro M., Trevani A., Geffner J., Jancic C.C. Neutrophils suppress T-cell function. European Journal of Immunology. 2013. doi: 10.1002/eji.201343664.
14. Schmidt S., Rainer J., Pioner C., Presul E., Rimi S., Kofler R. Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell death and differentiation. 2004; 11:45-6.
15. Zaika O.A., Dolmatova L.S. Cooperative apoptosis of coelomocytes of the holothurian Eupentacta fraudatrix and its modulation by dexamethasone. Advances in Bioscience and Biotechnology. 2013; 4:908-17.

# Химические науки

Гахраманов Р.Ф.<sup>1</sup>, Оруджев К.Дж.<sup>2</sup>, Шахгелдиев Ф.Х.<sup>3</sup>, Мамедова А.А.<sup>4</sup>

1 .  
 2 .  
 3 . . .  
 4 . . . ,

**SUMMARY**

Gahramanov R.F., Orujov K.S., Shahgeldiyev F.X., Mammadova A.A.

**INVESTIGATION OF THE NEW METHODS OF PARAFFIN HYDROCARBONS SEPARATION FROM KEROSENE FRACTION**

*Key words: paraffin hydrocarbon, kerosene fractios, -olefines, trichloroaluminium, additional products, peroxide of hidrogen sulphuric asid, petroleum synthesis.*

*It's known that the composition of petroleum contains not only paraffin hydrocarbons, but also aromatic and naphthene hydrocarbons as well.*

*At present in the petroleum chemistry synthesis paraffin hydrocarbon separation from kerosene fraction is one of the actual problems.*

*Taking this problem into consideration, the productive and effective method of paraffin hydrocarbon separation from kerosene fraction has been worked aut by us.*

, - -  
 - -  
 . - [3]. -  
 - -  
 . -  
 [1] , - α -  
 14-15% 55-57%, 28-30%. AlCl3. 0 - 70°C -  
 5 , - [4]. -  
 [2]. 350 – 380 °C 10 α - ,

AlCl<sub>3</sub>, - 1,4404, dA20 0,7979;  
 167) 1,1%, 75%  
 α - ;  
 AlCl<sub>3</sub> 2) 70 - 125°C/2  
 46,3 18,5%,  
 nD20 1,800, dA20 0,9560,  
 220. 1,7 -  
 - 1,0-1,5% -  
 - 2. 1.  
 - 210°C, . .  
 ; 274°C. , %: -  
 1:8,2:0,7-1:10:0,82 20-40°C 43,3,  
 - 56,7, nD20 1,4944, dA20 0,865,  
 - 197.  
 : 1) -  
 80°C 3 . 31,7  
 - (nD20 1,4542, dA20 0,8220;  
 - 170,1) 1,2%, 73,8 %  
 ;  
 2)  
 80°C - 135°C 3  
 . 43,2 19,1%  
 (nD20 1,4802, dA20 0,9647,  
 - 227,2), 1,5 .  
 1. 25°C - 0,2 0,8% -  
 75 ( . . 190°C,  
 . . 260°C, nD20 1,4439, dA20 0,780;  
 - 170,1; , %: - 3. 75  
 15,0, 28, 57 , 460 35%-  
 360 (35%- ), 37 29%-  
 37 (29%- ) 6% 30°C -  
 =0,44: 4,4: 0,31, 10 . Cl: 2 2  
 - 81 . 12,73%.  
 - 1) . . - 70°C/2  
 . 35 (nD20 1,4406, dA20 0,7979).  
 0,2% -  
 0,5%.  
 2) . . 70 - 125°C/2 . 46,5  
 (nD20 1,4857, dA20 0,9727),  
 - 24,3%. 1,5 .  
 (80 ) ( 11,1%).  
 -  
 -  
 1) 70°C / 2 . 32,0 (nD20

1. . . . , . . . . -  
 -  
 -  
 " " , 29-30  
 2009, .49-50  
 2. 199053, .260 – 674, 1970  
 3. . . . , .3, ., .74-75.  
 4. 438293, .10.G 43/04, 1974 5

**Аванесян . .<sup>1</sup>, Тимченко Л.Д.<sup>2</sup>, Писков .И.<sup>3</sup>**

1 « , -  
 2 « , -  
 3 , « , -  
 « - -  
 », .

**SUMMARY**

*Simple, accurate spectrophotometric method in the ultraviolet spectrum was developed for quantitative analysis of lovastatin. The absorption maxima of lovastatin in chloroform and ethanol, was determined. The range of detectable concentrations of lovastatin was reported. The minimum concentration of lovastatin, a sensitive spectrophotometric analysis was fixed. The developed method has been tested on the parameters of linearity and relative measurement error. Spectrophotometric quantitative analysis of lovastatin tested pharmacological drugs.*

*Keywords: spectrophotometry, lovastatin, absorption spectrum, the absorption maximum.*

- (2S)-2- ( 24 3  
 - 6 5) -  
 - , -  
 , - - [6].

[2].

[4].

[7, 9],

[10, 13].

[8].

-102 ( ).

99,6% ( ).


10 / ( .1).

513 [12].

max=242  
 , max=238

0,04 0,40 / .

[1] 7



. 1 –

10 / .

5 / ; 2) 0,1  
 9,9 ( ) –  
 : 1) 50  
 10 ( ) –  
 1 / 15 /  
 ( ).

	( )	( )		max=242	max=238
1	3,92	0,08	1,0	0,052	0,093
2	3,84	0,16	2,0	0,165	0,182
3	3,60	0,40	5,0	0,287	0,434
4	3,40	0,60	7,5	0,432	0,635
5	3,20	0,80	10,0	0,559	0,847
6	3,00	1,00	12,5	0,637	1,022
7	2,80	1,20	15,0	0,804	1,140

5%), [5].

Biostat 4.03.

r=0,995 r=0,997,


2)

1-12,5 / . 1-15 / ,


'1/2max) [3],

( 1/2max–

2,8% – 2,9% ( . 3,4).




. 2 –



. 3 –

( / )



. 4 –

( / )

1. ... 2006. (4). 8-12.

2. ... 2006. 5. (6) 46-52.

3. ... 1976. 376 .

4. ... 2011 (1). 77. 21-28.

5. ... : « »; 1975. 462 .

6. ... 2009. 1632 .

7. ... (Pleurotus ostreatus):

8. ... 2006. (4). 8-12.

- ... -  
« », 2013. 224
8. Biljana Nigovi , Miranda Serti , Ana Mornar. Simultaneous determination of lovastatin and citrinin in red yeast rice supplements by micellar electrokinetic capillary chromatography. *Food Chemistry*. 2013. Vol. 138. Issue 1. P. 531-538.
  9. Clinton W. Yang, Shaker A. Mousa The effect of red yeast rice (*Monascus purpureus*) in dyslipidemia and other disorders. *Complementary Therapies in Medicine*. 2012. Vol. 20. Issue 6. P. 466-474.
  10. Jiang Wang, Jasmine A. Luzum, Mitch A. Phelps, Joseph P. Kitzmiller. Liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of simvastatin, lovastatin, atorvastatin, and their major metabolites in human plasma. *Journal of Chromatography*. 2015. Vol. 983-984. P. 18-25.
  11. Markopoulou C.K, Koundourellis J.E. Two derivative spectrophotometric methods for the simultaneous determination of lovastatin combined with three antioxidants. *Journal of Pharmaceutical and Biomedical Analysis*. 2003. Vol. 33. Issue 5. P. 1163-1173.
  12. Mohie M.K. Sharaf El-Din, Khalid A.M. Attia, Mohamed W.I. Nassar, Mohamed M.Y. Kaddah Colorimetric determination of simvastatin and lovastatin in pure form and in pharmaceutical formulations. *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy*. 2010. Vol. 76. Issues 3-4. P. 423-428.
  13. Sanjay Kumar, Nalini Srivastava, Bhaskar Sen Gupta, Ramesh Chander Kuhad, James Gomes. Lovastatin production by *Aspergillus terreus* using lignocellulose biomass in large scale packed bed reactor. *Food and Bioproducts Processing*. 2014. Vol. 92, Issue 4. P. 416-424.

# Фармацевтические науки

**Федотова А.А.<sup>1</sup>, Аюпова Г.В.<sup>2</sup>, Катаев В.А.<sup>3</sup>**

1 . . . ,

;

2 . . . ,

;

3

. . . , . . . , . . . , . . .

[3].  
[1,2].  
Ultrez 10

**ABSTRACT**

*Compositions of adsorptive vaginal gels for the treatment of bacterial vaginosis have been established. Using IR spectroscopy we have found that there is no technological interaction between sorbents and gel bases. [3]. We optimized ratio of sorbent gelling agent By rotational viscometry [1,2]. Interaction of enterosgel and polysorb with standard gel-forming compounds carbopol of Ultrez 10 brand in the composition of vaginal adsorbing gels for the treatment of bacterial vaginosis has been studied. The paper presents the results of studies of general toxicity, irritant and local allergic action adsorptive hydrophilic gels polysorb and enterosgel. The obtained dates allow to conclude that sorption gels do not have a general toxic, irritant and local allergic action.*

*Key words: sorbent, gel-forming substance bacterial vaginosis, hydrophilic gel, polisorb, enterosgel*

,  
 ,  
 [1,2,3].  
 ( ) - ( 42-3603-98)  
 ( ) - ( 42-3731-99).  
 Ultrez 10.  
 15 % 10  
 % 2 6 12  
 ,  
 « )  
 » (2005).  
 24  
 Wistar, 4  
 15 % . 10% .  
 0,35 % . 7  
 3,0 2,5×2,5  
 , 60 ,  
 ,  
 15, 30 60  
 ,  
 ),  
 2,0-2,3 ,  
 «  
 ».

15 % 10 %

1. . . . .

// . . . . .

- 2014. . 9. 6. . 70-72.

2. . . . .

// . . . . .

. . . . . // . . . . .

. 2008.

15. 4. . 85-89.

5- 3. . . . .

// . . . . .

// . . . . .

- 2013 4, . 68-71

# Ветеринарные науки

Чекалин Н.Ю.<sup>1</sup>, Овчаренко Т.М.<sup>2</sup>, Дерезина Т.Н.<sup>3</sup>

1 «  
2 «  
3 «

## COMPREHENSIVE FARMACOCINETICA IMMUNE STATUS AND THE LEVEL OF TRACE ELEMENTS MEDICATION "NIKA-EM" IN COWS DURING PREGNANCY

*Chekalin N.Y., graduate student The Don State Agrarian University.*

*Ovcharenko T.M., associate Professor of Department of therapy and propaedeutics The Don State Agrarian University, candidate of veterinary Sciences*

*Derezina T.N. head of the department of therapy and propaedeutics, The Don State Agrarian University, doctor of veterinary Sciences, Professor*

7 « - » 0,05

A, M, G

“ - ”

### SUMMARY

*In article questions of the safest and most optimal method of increasing immunological parameters of the organism of pregnant cows and correction of the level of trace elements during pregnancy and after childbirth. We offer comprehensive scheme pharmacocorrection immune status and the level of trace elements is administered by subcutaneous drug "NIKA-EM" in a dose of 0.05 ml per kg body weight three times with an interval of 7 days a month before calving. Presents the results of immunological studies of blood in cows of the experimental group after the experiment indicate increased levels of immunoglobulin classes A, M, G, and major trace elements in hair samples, which confirms the increased level of nonspecific resistance and proves high immunomodulatory activity of the drug "NIKA-EM" in the correction of immunodeficiency States, developing on the background of alimentary disorders of metabolism in cows during pregnancy and the postpartum period.*

*Key words: zinc, immunoglobulins, immune deficiency, cows, immunotherapy, immunomodulator "NIKA-EM"*

,  
 - ,  
 ,  
 [7, 8].  
 «  
 »,  
 ( . - - ).  
 «  
 »  
 [1, 2, 3, 5, 9].  
 «  
 »  
 15 8-  
 [4, 6, 10]. « - » 0,05  
 ( 7 15-20 )  
 “ - ”,  
 :  
 StatFax 303+ “ ”.  
 ( ) -001  
 ( ).  
 / ; - 0,254 / ; 0,48  
 - 19,4 / . - 0,1 / ;  
 «  
 »

( .1).  
 91,3±0,8  
 / ,  
 (Zn - 62,8±0,9 14,0±0,2  
 / ; 63,5±0,5 / ), - / , - 110,3±2,7 / -  
 45,7±1,1 / , -  
 (Cu -15,0±0,7 / ; 17,0±0,3 / ), .  
 123,4±3,0 / 120,2±2,5 / ( .  
 2).

1

	Cu, /	Fe, /	Zn, /
	2,01±0,05	103,81±0,30	20,59±2,50
	2,85±0,09	412,43±5,80	25,66±1,07
	3,32±0,07	150,71±3,07	28,91±0,90
	2,47±0,04	108,47±7,00	23,39±0,80
	2,93±0,07	678,67±34,07	32,57±2,00

2

	28-			28-		
Cu, /	15,0±0,7	14,7±0,3	15,6±0,5	17,0±0,6	15,9±0,7	14,0±0,2**
Fe, /	123,4±3,0	119,6±1,0	122,3±3,2	120,2±2,0	115,0±1,9	110,3±2,7**
Zn, /	62,8±0,9	76,8±0,4	91,3±0,8***	63,5±0,5	50,2±0,6	45,7±1,1**

: \* - <0,05; \*\* - <0,01; \*\*\* - <0,001

- / ; - 1,1±0,02  
 , - / ; 12,17±0,2 / ; 0,94±0,1 / -  
 ( .3), -  
 1,14±0,05 / ; G -  
 13,67 ±1,4 / ; - 1,0±0,2

3

	28-			28-		
IgG, /	13,67±1,4	19,67±1,47*	20,05±1,07*	12,17±0,2	14,17±0,24	10,35±0,56*
IgA, /	1,14±0,05	1,44±0,07*	1,71±0,03**	1,1±0,02	0,9±0,01	0,76±0,08
IgM, /	1,0±0,2	1,72±0,19*	1,85±0,1**	0,94±0,1	0,8±0,12	0,62±0,02

: \* - <0,05; \*\* - <0,01; \*\*\* - <0,001



( . 3). - 4. , . . - / . . -  
: Ig G - 20,05±1,07 / ; Ig A - , 1993. - .98-104.  
1,71±0,03 / ; Ig M - 1,85±0,1 / ; - 5. , . . -  
93,7%; 125%; 198% , - / . . ,  
. . . // « -  
, - » - -  
- - : «  
», 2006. - .46-51  
6. . . / . . -  
, . . , . . -2012.-  
// . -101-108.  
7. , . . / . . , . .  
// . . :  
1. , . . / . . - . - -  
, . . , . . - , 1998. - .3-7.  
2. - - : « », 2005. - 177 . 8. , . . / . . , . .  
, . . / // . . - -  
. . . // « - , 2001. - .192-197.  
9. ,  
k d b c , 190  
».- -  
.- .3. - . , 2007. - .5-7.  
3. , . . : -  
/ . . -  
// . . , 2003.-  
.2(6).- .47-49.



Международное Научное Объединение "Inter-Medical"